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Abstract 
 
  
Neurons within different brain regions have varying levels of vulnerability to external 
stress and therefore respond differently to injury. A potential reason to explain this may 
lie within a key lipid class of the cell’s plasma membrane called gangliosides. These 
glycosphingolipid species have been shown to play various roles in the maintenance of 
neuronal viability. The purpose of this study is to use electrospray ionization mass 
spectrometry (ESI-MS) technique and immunohistochemistry to evaluate the temporal 
changes in the expression profiles of various ganglioside species during the course of 
neurodegeneration in rat primary cortical neurons exposed to glutamate toxicity. Primary 
embryonic (E18) rat cortical neurons were cultured to DIV14. Glutamate toxicity was 
induced for 1, 3, 6 and 24 h. Immunofluorescence was used to stain for GM1 and GM3 
species and ESI-MS was used to quantify the ganglioside species expressed within these 
injured neurons, which were compared to expression profiles of healthy neurons. 
Neurons were also pretreated with GM1 24 h before glutamate exposure to assess the 
level of neuroprotection conferred by GM1. Microglia were also activated using amyloid 
beta oligomer and stained for GM1 and GM3 expression. ESI-MS data revealed that 
d16:1 and d18:1 GM1 species were upregulated in neurons exposed to glutamate while 
no significant changes were observed for GM2 and GM3 expression. Furthermore, 
neurons that were pretreated with GM1 showed increased viability compared to untreated 
neurons when exposed to glutamate. Immunofluorescence revealed an elevated 
expression of GM3 in activated microglia compared to controls. These data suggests that 
different gangliosides and cells within the CNS play diverse roles in the process of 
neurodegeneration. 
 
Keywords: Glutamate Toxicity, Neurons, Central Nervous System, Neurodegeneration, 
Gangliosides, GM1, GM2, GM3, Neuroinflammation, Electrospray Ionization Mass 
Spectrometry, Microglia 
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1.1 Brain Vulnerability 
 As	  humans	  age,	  they	  become	  more	  prone	  to	  injuries	  and	  diseases	  related	  to	  the	   brain.	   However,	   different	   regions	   of	   the	   brain	   have	   varying	   levels	   of	  vulnerability	  to	  external	  stress	  and	  injury. For example, in Alzheimer’s Disease (AD), 
the most severely affected areas of the brain include the cortex as well as the 
hippocampus1. With ischemic stroke, the CA1 region of the hippocampus is more 
vulnerable than the granule cells of the dentate gyrus2. Furthermore, in Parkinson’s 
Disease (PD), the neurons in the substantia nigra are primarily affected and die from 
oxidative stress3. Considering that the plasma membrane of the neurons is the first site of 
exposure to any changes to the external environment, its physical structure may hold the 
key to explaining the brain’s differing levels of vulnerability to toxic insults. Therefore 
studying the physical structure and composition of the plasma membrane and how it 
regulates itself during stress is important as it may give us an insight in explaining the 
differential vulnerability of neurons to toxic environments. 
 
 
1.2 Plasma Membrane  
 
The plasma membrane of cells is a heterogeneous structure composed of 
numerous proteins, phospholipids, cholesterol, and sugar molecules4. The plasma 
membrane is also a dynamic structure that is able to adjust its fluidity and density by 
changing its lipid composition depending on the extracellular environment5. It is believed 
that when animal cells undergo mitosis, half of the phospholipids of the plasma 
membrane are degraded and turned over for every one or two cellular divisions6,7. It is 
hypothesized that the reason for this significant turnover is linked to the cell’s viability 
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and its attempt to repair any damages that occurred within the plasma membrane6. Cells 
with inability to turnover their plasma membrane lipid compositions are associated with 
diseased states such as lysosomal-storage diseases8, indicating that the integrity of the 
cell’s membrane is essential for survival. This bilayer structure also consists of lipid rafts 
that are rich in cholesterol and saturated lipid species such as sphingolipids that form an 
organized dense cluster that is distinct from the surrounding environment9. These lipid 
rafts have various roles within the cell including signal transduction as well as sorting and 
trafficking of materials including cholesterol and proteins, through secretory and 
endocytic pathways10. Within the lipid rafts, one of the major lipid species is 
gangliosides. Gangliosides are present in the lipid rafts of plasma membrane of virtually 
all cells, but are particularly abundant in neuronal cells11.  
 
 
1.3 Ganglioside Structure 	  
Gangliosides have ampiphilic properties and are mainly located within the outer 
leaflet of the plasma membrane of all vertebrate cells11. Their hydrophobic carbon tails 
are embedded within the membrane while their polar and bulky oligosaccharide moieties 
face the external environment. This property allows the gangliosides to interact with the 
soluble molecules as well as other hydrophilic components of other cells in the 
periphery12. Although gangliosides and other glycolipids constitute small portions of total 
glycoconjugates, the levels of these sialic acid bound lipids are abundantly expressed in 
the central nervous system (CNS), comprising 5-10% of all lipid mass of neuronal 
membrane13. Gangliosides are glycosphingolipids (GSL) – ceramide base and 
oligosaccharide chains – with differing numbers of sialic acid residues attached to the 
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sugar chains14 (Fig. 1). In the lipid moiety, amino-alcohol is linked to the fatty carbon 
chain by an amide linkage15. In the mammalian brain, the d18:1 and d20:1 sphingosine 
chains that contain a trans double bond at position 4-5 in the ceramide component are the 
most commonly found15 while the d16:1 gangliosides were only found in trace amounts 
in rat brains16. Sialic acid residues are usually linked to other sialic acid residues, or 
galactose, at the terminal end of the molecule. The most common form of sialic acid that 
is found in mammals is the N-acetylneuraminic acid although the less common forms, N-
glycolylneuraminic acid are also observed in some cases17. The large sugar chains and the 
negative charge on the sialic acid forms a large shell of water, requiring a larger area in 
comparison to other neutrally charged phospholipid species15. This allows gangliosides to 
form rigid domains of high density, called the lipid rafts, that are separated from other 
glycolipids. The lipid rafts are also stabilized by hydrogen bonds with the water and the 
amide group of the sphingosine18 which further adds to the rigidity of the structure.  
Gangliosides can also be further classified in to various series. Gangliosides with 
0, 1, 2 or 3 sialic acid residues attached to the galactose unit are respectively termed 
asialo, a, b, and c-series, while those gangliosides that have sialic acid residues linked to 
the N-galactosamine unit are termed α-series ganglioside19. The expression pattern of 
gangliosides differs based on cell type and their quantities are also regulated based on the 
stage of embryonic development20,21.  
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1.4 Ganglioside Synthesis  	  
Ganglioside expression profiles change depending on the cell type as well as the 
stage of their development22. Their expression profile is highly dependent on the balance 
of synthetic and catabolic processes as well as specific intracellular trafficking22. The 
ceramide tails, which are hydrophobic, act as anchors in the plasma membrane and are 
formed on the membrane of endoplasmic reticulum (ER). The ceramide is then further 
Figure 1. Ganglioside structure. Adapted from Schengrund 2015166 
Ceramide	  Base	  
Sugar	  Chains	  
Sialic	  Acid	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modified and glycosylated within the Golgi apparatus by glucosylceramide synthase, 
which converts the ceramide into glucosylceramide23. Complex GSL are further modified 
in stepwise fashion by the addition of various sugars such as galactose, and N-
acetylgalactosamine.  
 The precursor to all gangliosides is GM3 ganglioside which is produced by the 
CMP-sialic acid:LacCer α2-3 sialytransferase (ST1)24–26. This enzyme converts 
lactosylceramide by adding sialic acid in a α2-3 bond to lactosylceramide, forming GM3. 
Then GM3 can be further modified by stepwise addition of more sialic acids by cytidine-
5′-monophosphate (CMP)-sialic acid: GM3 α2-8 sialyltransferase (ST-2) and CMP-sialic 
acid: GD3 α2-8 sialyltransferase (ST-3) forms GD3 and GT3 sequentially. GM3, GD3, 
and GT3 serve as precursors for a-,b-, and c-series respectively. From these molecules, 
various glycosyltransferases including UDP-GalNAc β1-4 N-
acetylgalactosaminyltransferase (GalNAcT), UDP-Gal β1-3 galactosyltransferase, CMP-
sialic acid: α2-3 sialyltransferase, CMP-sialic acid α2-8 sialyltransferase produce more 
complex gangliosides in the pathway in a sequential manner24,25.  
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1
Figure 2. Ganglioside biosynthesis pathway. Ganglioside synthesis starts with a ceramide 
base followed by a sequential addition of sialic acid and sugar residues by various enzymes. 
Cer: ceramide, GalNAc T: N-acetyl galactosaminyltransferase or GM2/GD2/GT2 synthase, Gal 
T1: galactosyltranferase I, Gal T2: galactosyltranferase II or GM1 synthase, Glc T: 
glucosyltransferase, ST1: sialyltransferase I or GM3 synthase, ST2: sialyltransferase II or GD3 
synthase, ST3: sialyltransferase III or GT3 synthase, ST4: sialyltransferase IV or GD1a 
synthase, ST5: sialyltransferase V or GT1a synthase. Figure adapted from Yu RK et al. 2004. 	  	  
2
a	  -­‐	  pathway	  asialo	  -­‐	  series	   b	  -­‐	  pathway	   c	  -­‐	  pathway	  
GM1b	  
GT1a	  GD1c	  
GD1a	   GT1b	  
GQ1b	  
GQ1c	  
GP1c	  
GA2	  
GM1	  GA1	  
GM2	   GD2	  
GD1b	  
GT2	  
GT1c	  
GT3	  GD3	  LacCer	   GM3	  
GlcCer	  
Ceramide	  Glc	  T	  
Gal	  T1	  
ST1	   ST2	   ST3	   GalNAc	  T	  
Gal	  T2	  
ST4	  
ST5	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1.5 Ganglioside Expression in the Nervous System 
  
Gangliosides are the main glycolipids in the neurons and studies indicate that the 
expression patterns of gangliosides differ as the mammalian brain develops. For example, 
in mice, there is an 8-fold increase in total ganglioside in adult brains compared to those 
of embryonic mouse brains20. There is also a turnover from an abundance of simple 
ganglioside such as GM3 and GD3 to more complex species such as GM1, GD1a, GD1b 
and GT1b as the mouse brain matures from embryos. Studies with matrix assisted laser 
desorption/ionization mass spectrometry (MALDI-MS) imaging demonstrated that GM3 
is below detection threshold in healthy adult mouse brains in situ27. Similarly, the 
quantity of gangliosides increase 3 fold in humans from the level of gestational weeks to 
infantile stage. More complex species such as GM1 and GD1a levels are increased to 12-
15 fold during this development as well28. The main ganglioside species within adult 
human brain are GM1, GD1a, GD1b, and GT1b23. The key to the change in the 
expression shift from simple to complex ganglioside lies in the changes in the activity of 
enzymes involved in the gangliosidic pathways. For example, the activity level of ST-II 
decreases during development while GalNAcT increases, which promotes expression of 
more complex ganglioside down the a-series29 pathway. 
 
1.6 Ganglioside d18:1 vs d20:1 Sphingosine Moieties 	  
The sphingosine moieties of gangliosides also vary within their carbon chain 
lengths.  Specific lengths of these carbon chains have been shown to be expressed in 
different regions of the brain and may be associated with unique roles within the CNS. 
Specifically, GM1 d18:1 has been shown to be expressed ubiquitously in the healthy rat 
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brain while GM1 d20:1 was heavily concentrated within the dentate gyrus of the 
hippocampus27. Studies indicate that d20:1 sphingosine moiety of gangliosides are 
primarily expressed only within the nervous systems30–32. Furthermore, higher amounts of 
d20:1 are found in brains of older mammals than those of younger counterparts. For 
example, in rat cerebellum, the d20:1/d18:1 ratio from 8 day old animal to 2 year old 
animal increased for GQ1b, GT1b, GM1, GD1b and GD1a, indicating that d20:1 
gangliosides are associated with aging of the brain33. Total lipid extracts from human and 
many other mammalian fetuses contained mostly d18:1 species and a negligible amount 
of d20:1 species. As the brain matures, the levels of d18:1 remain relatively stable or 
decreases insignificantly34,35. These findings may suggest that the ratio between the d18:1 
vs d20:1 species may be markers of aging15. 
 
1.7 Ganglioside Degradation 	  
Degradation of gangliosides occurs via the endosome and lysosome pathways. 
Each step requires an acidic environment and uses the H+ to reduce and hydrolyze the 
molecule, which enters into the organelles by proton pumps36. Gangliosides are degraded 
by glycosidases, which are soluble enzymes in the lumen of endosomes and lysosomes, 
starting with the non-reducing terminal monosaccharide unit of the ganglioside sugar 
chains37. Eventually, ceramide is degraded into its fatty acid component and sphingosine 
by ceramidase23,36. When gangliosides are endocytosed into the cell, the endocytosed 
vesicle containing the gangliosides merges with the early endosome. The endosome 
further invaginates, which allows the gangliosides to face the external environment 
within the endosome. This vesicle is transported and merges with the lysosome. Through 
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the merging of the vesicle and the lysosome, the ganglioside is degraded by the 
lysosomal glycohydrolases (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Ganglioside degradation pathway. Degradation of gangliosides occurs through 
endosomal and lysosomal enzyme pathway. Adapted from Schulze et al. 2009165 
Gangliosides 
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In the initial step in the ganglioside degradation pathway, the more complex 
gangliosides with multiple sialic acid residues such as GT1b and GQ1b are converted to 
GM1. Then galactose is removed from GM1 to produce GM2 by β-galactosidase. 
Subsequently, the action of β-N-acetyl-hexoaminidase cleaves off N-acetyl-galactosamine 
from GM2 to produce GM3. Sialic acid residues can also be directly cleaved from GM1 
or GM2 by specific sialidases which produces asialoganglioside GA1 and GA2 which are 
converted to Lac-ceramide38–40. Lac-ceramide is then further degraded by β-galactosidase 
and β-glucosidase into ceramide. Most of the degradation processes that occur in the 
lysosomes require lipid binding glycoprotein molecules called saposins37, which act as 
transfer proteins that dislodge the gangliosides from the membranes and deliver them to 
the hydrolases37.  
 
 
1.8 Ganglioside Function 	  
Gangliosides have demonstrated to play various roles within the mammalian 
body. For example gangliosides are believed to be receptors for microbial toxins; GM1 
ganglioside within the brain and epithelial cells of the intestines bind to choleratoxin41. B-
series gangliosides within the nervous tissue also act as receptors for tetanus toxin 41,42.  
Gangliosides have also shown to mediate cell adhesion in blood cells. One way in 
which this is mediated is through proteins such as lectin that bind through carbohydrates 
and recognize specific glycolipids. For example, one class of lectin known as selectins 
are able to recognize and bind to sialyl-fucosyl-LacNAc sugar sequences of 
glycolipids43,44. Gangliosides also affect growth of tumor cells by interacting with growth 
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factor and integrin receptors45. Although the exact mechanism of growth modulation is 
not understood, ganglioside GM3 seems to interact with N-glycosylation of the epidermal 
growth factor (EGF)46 receptor. GM3 has also been shown to play roles in cellular 
motility. Integrin α-3 and membrane protein tetraspanin CD9 forms a complex with GM3 
that inhibits laminin-5 dependent motility. Studies on colorectal and bladder carcinoma 
cells showed inhibition in motility when GM3, CD9 and integrin α-3 were co-
expressed47,48.  
In the CNS, studies indicate that gangliosides are required for normal 
development of the brain for survival, proliferation and differentiation of the neurons. For 
example, mice that are deficient of GlcCer synthase, which converts the ceramide into 
glucosylceramide23, suffers from embryonic lethality due to its inability to differentiate 
ectodermal layer of the germ layer49. Furthermore, mice that were deficient in GlcCer 
synthase specifically in neurons showed loss of structural integrity of the cerebellum as 
well as disrupted function and die within three weeks of birth50. Additionally, mice that 
were knocked out for ST-II enzymes, which synthesize b-series gangliosides, also 
showed delayed hypoglossal nerve regeneration after damage51. When formation of more 
complex gangliosides was inhibited by GalNAcT knock-out, leaving mainly GM3 and 
GD3, myelin formation was defected, axons showed degeneration, and conduction 
velocity was decreased from the tibial nerve to the somatosensory cortex52,53. When 
GalNAcT and ST-II were both knocked out in mice, which only expresses GM3, mice 
died in response to acoustic-induced seizures54. Furthermore, in humans with mutation 
that had a defective ST-I gene which limited ganglioside expression to just the a-series 
showed infantile-onset epilepsy syndromes55. A loss of function mutation in the GM3 
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synthase gene also lead to infantile progressive brain atrophy, epilepsy and chorea, which 
are all symptoms that resemble that of juvenile Huntington’s Disease (HD)55. All of these 
studies indicate that gangliosides play important roles in the maintenance of the structural 
integrity including axonal and myelination, stability, and signal transduction within the 
CNS. 
1.9 GM1 Ganglioside and the Central Nervous System 
 
Monosialic acid ganglioside GM1 is one of the more prominent gangliosides 
within the adult human brain23 and is a major lipid component within the lipid raft of 
many cell types56,57. GM1 has been linked to neuronal growth, protection, and repair in 
cell cultures and animal models of aging and injury58. GM1 has been shown to activate 
neurotrophic effects of nerve growth factor (NGF) in vivo by interacting with its 
receptors59,60. Specifically, it has been shown to activate NGF receptor (Tyrosine Kinase 
Receptor A) by promoting phosphorylation and dimerization61,62. Through its 
neurotrophic like-activity, it is able to stimulate neurite growth, prevent degeneration, and 
has even been shown to have repair effects on motor spinal neurons after injury and 
aging63. When taken into clinical setting of spinal cord injury (SCI), intravenous 
administration of GM1 to patients of SCI showed a trend in the improvement of spinal 
cord activity including motor, light touch, and pinprick scores, bowel/bladder function, 
anal contraction, although it was not significant. The patients with the less severe form of 
the SCI showed the most benefit with GM1 treatment64. 
 Striatal neurons and fibroblasts attained from HD patients displayed lower levels 
of GM1 synthesis and expression and the cells were more susceptible to apoptosis65. 
When GM1 synthesis was inhibited in wild-type striatal cells, the level of apoptotic 
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susceptibility was increased to those of HD striatal cells65. These findings suggest that 
reduced levels of GM1 might lead to the symptoms and progression of HD. Finally, when 
GM1 was re-administered to HD striatal cells, there were increased levels of 
phosphorylation of the Htt mutant protein that is responsible for the toxic properties of 
HD and improved the survival of the HD striatal cells65. These findings indicate that 
GM1 may be used as a potential therapeutic target to treat HD due to its neuroprotective 
property. 
 GM1 also has the ability to interact with various proteins to promote 
neuroprotection. For example, growth-associated protein 43(GAP43) is a protein that is 
expressed in the membrane of neurons which is highly expressed during axonal growth, 
and the development and regeneration of the CNS and peripheral nervous system (PNS). 
Specifically, GAP43 has been shown to be upregulated during spinal cord regeneration66. 
When spinal cord neurons were injured with glutamate toxicity and treated with GM1 
and NGF, the levels of GAP43 mRNA increased significantly more than when treated 
with NGF or GM1 alone, suggesting that GM1 acts synergistically with NGF to provide 
neuroprotection67. Additionally, when the optic nerve is severed, the retinal ganglion cells 
(RGC) undergo degeneration from lack of neurotrophin (NT), altered gene expression, 
and increased oxidative stress68–72. However, the RGC’s survival has been shown to 
increase by treatment with various neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF), NGF, and NT3 or NT473,74; these neurotrophic factors 
activate the mitogen-activated protein kinase (MAPK) pathway75. MAPK and 
phosphatidylinositol 3-kinase (PI 3-K) are known to target cAMP response element-
binding protein (CREB)76 which is believed to be involved in intrinsic survival program 
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of the cells. Similar to how these growth factors increased the viability of severed RGC, 
exogenous GM1 treatment on the severed RGC increased their survival by enhancing the 
activation of MAPK and CREB. Furthermore, when these cells were co-treated with 
MAPK inhibitor PD98059, the GM1 protection was negated and phosphorylation and 
activation CREB was not observed77. This suggests that the pathways in which GM1 
provides neuroprotection is through the MAPK and/or the PI 3-K pathway78,79 (Fig. 4).  
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Figure 4. MAPK pathway induced by GM1. Mitogen activated protein kinase 
(MAPK) induces phosphorylation of cAMP response element binding (CREB) 
protein that promotes neuronal survival and plasticity. Figure adapted from 
Walton MR et al. 200076. 
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GM1 has also demonstrated effective neuroprotection in various ischemic models. 
Rats that suffered from ischemic damage by the occlusion of left middle cerebral artery 
showed decreased infarct volume when GM1 was administered intravenously, compared 
to those who were not treated with GM180. Another study looked at the level of activity 
of Na+ and K+ ATPase to assess the level of ischemic damage done by ischemic injury in 
rat models. While the levels of Na+ and K+ ATPase activity decreased in the peri-
ischemic areas by 42-59%, there was no significant loss of this activity when treated with 
GM1. The primary ischemic area was also reduced compared to those that were not 
treated with GM181. When rats underwent ischemic damage, levels of various fatty acids 
was substantially depleted including palmitic, stearic, oleic, and arachidonic acids which 
indicate that ischemia irreversibly changes and damages the plasma membrane of 
neurons. However, the acute treatment with GM1 showed partial restoration and 
prevented loss of these species of fatty acids within the primary area of ischemic damage 
and complete restoration in peri-ischemic areas81. Extending beyond rat models, when 
fetal sheep were pretreated with GM1 and given continuous infusion of GM1 after 
hypoxic insult, it showed reduction in the neuronal loss and improvements in electrical 
activity, primary and secondary edemas82. However, when GM1 treatment was taken into 
clinical trial, no significant improvements were found on stroke patients who were treated 
with GM1. In some cases, patients suffered from adverse effects including skin irritation, 
and developed Guillain-Barre syndrome83.  
One disease in which GM1 had promising results in a clinical setting was PD. 
Prior to clinical trials on humans, animals models were used to test the effect of GM1 on 
PD. For example, mice that were treated with GM1 and 1-methyl-4-phenyl-1,2,3,6-
	   17	  
tetrahydropyridine (MPTP) showed an increase in L-dopa compared to those that were 
only given MPTP84, suggesting that GM1 increases dopamine synthesis. Furthermore, 
primates who were given MPTP also improved their PD symptoms through treatment 
with GM1. Primates who were given GM1 treatment also showed increased levels of 
striatal dopamine levels and its metabolites, and also showed increased levels of 
dopaminergic innervation in the striatum. In summary, in animal models of MPTP-
induced PD, GM1 treatment repaired damaged substantia nigra dopamine neurons, 
increased the levels of dopamine in the striatum and promoted dopamine synthesis85–88. 
When GM1 treatment was taken to clinical stage, it showed promising results. When PD 
patients were given intravenous GM1 administration, they showed improvements in their 
motor symptoms according to the Unified Parkinson’s Disease Rating Scale (UPDRS)89. 
In AD, one of the hallmark features is accumulation of amyloid-β-peptide and 
evidence of oxidative stress, such as an increased levels of lipid peroxidation, and 
increased oxidation of DNA and proteins, which all cause injury and death of neurons90. 
One way in which GM1 counteracts reactive oxygen species is by increasing catalase 
activity in the brain as shown in rat cortical brains in vivo91. Catalase is an enzyme that 
breaks down H2O2 into water and molecular oxygen and plays an important role in 
reducing the levels of oxidative stress in the cells. However, some studies indicate that 
since amyloid-β-peptide is formed in the membranes, it can interact with GM1, which 
may facilitate the formation of toxic fibrils that accelerates the progression of the 
disease92–94. On the other hand, many studies suggest neuroprotective roles of GM1 in 
AD models. When PC12 cells (cells derived from tumor of rat pheochromecytoma. When 
exposed to NGF, their phenotype changes to those of sympathetic neurons95) were 
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transfected with Swedish-type mutant beta amyloid precursor protein (APPsw) mutation 
to model AD, the PC12 cells showed increased sensitivity to oxidative stress. Once the 
cells were exposed to H2O2 or amyloid-β protein, Na+, K+ ATPase was partially 
inactivated and there was a production of malonyldialdehyde, which is a marker for 
oxidative stress. However, this was prevented by treating the cells with GM1 
ganglioside96. When organotypic hippocampal neurons from rats were treated with as 
little as 10 µM of GM1, neuroprotection from Aβ25-35 toxicity was measured by 
decreased levels of propidium iodide (PI) uptake97. This group also showed that 
pretreatment of the neurons with GM1 reduced the level of dephosphorylation of 
glycogen synthase kinase 3 beta (GSK3β) (activation) which is a pathway that triggers 
apoptosis in animal models of AD98. GM1 has also been shown to have antioxidant 
properties by directly scavenging for hydroxyl radicals and superoxide anions99.  
 
1.10 GM2 Ganglioside 
 
GM2 ganglioside is formed from GM3 by the addition of N-acetylgalactosamine 
by N-acetylgalactosaminyltransferase19. Previous studies with MALDI imaging showed 
that the levels of GM2 was below threshold of detection in healthy mice brains but was 
increased around the infarct region after mice suffered ischemic stroke through middle 
cerebral artery occlusion (MCAO)27.  In the ferret brain, GM2 has also been shown to be 
more prominent during development of the brain where it was detectable from post natal 
day 1 to 21, but disappeared by adulthood100. Furthermore, in the brains of mouse models 
of osteopetrosis associated transmembrane protein 1(OSTM1)-dependent osteopetrosis 
that shows various forms of neuropathology including retinopathy, and cortical atrophy, 
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there was an accumulation of GM2 in the lysosomes, although, the ganglioside enzymatic 
activities were similar to control animals101. Since the enzymatic activities were not 
affected, it suggests that GM2 accumulation may stem from degradation of GM1 in the 
neurons. It is yet unclear as to whether GM2 is responsible for the neurodegenerative 
phenotype. However there is an association of GM2 and neuronal death particularly 
because GM2 accumulation has been shown in lysosomal storage diseases including, 
Sandhoff and Tay-Sach’s disease, and Niemann-Pick C disease and in vesicular 
organelles in mucopolysaccharidoses101–104, all of which show neuronal death.  
Mice brains that were treated with ethanol showed increase in GM2 in the 
mitochondrial and lysosomal fractions. Immunohistochemistry also indicated increase in 
GM2 staining in the microglia of these brains105. This opens the possibility that GM2 
expression patterns observed in brain tissue may arise not from cortical neurons but other 
cells within the brain. 
In AD models of mice that express APP Swedish and London mutations, levels of 
GM2 were markedly increased in the cortex106. Similarly, GM2 levels were also elevated 
in the frontal and parietal cortex of AD patients107. This may be due to an accelerated 
degradation in the lysosomes to simpler gangliosides in AD patients as fibroblasts from 
AD patients have been shown to increase the degradation of GM1 to produce more 
GM2108.  
 
 
1.11 GM3 Ganglioside 
 
GM3 is the simplest ganglioside in the biosynthetic pathway and is a precursor to 
all gangliosides24. In many different cell types including fibroblasts and cancer cells, 
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GM3 has been shown to interact with receptors that are linked to angiogenic pathways 
including insulin-like growth factor 1 (IGF-1) basic fibroblast growth factor (b-FGF), 
EGF, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), 
cell adhesion molecules such as integrins 109–116. Compared to other gangliosides such as 
GT1b, which promotes angiogenesis, GM3 inhibited endothelial proliferation in human 
tumor cells. When the tumor cells were re-incubated in media that lacked GM3, they 
showed regrowth of endothelial cells117. In rabbit cornea, angiogenesis was repressed by 
GM3 while it was promoted by GM1 or GD3. Furthermore, motility of microvascular 
endothelium was significantly reduced with the addition of GM3, which was restored 
when GD3 was further added118. GM3 has also shown to prevent cell proliferation by 
interfering with growth factor receptors. GM3 has been shown to interfere with binding 
of EGF with its receptor which is essential for cellular proliferation46. When GM3 was 
introduced to keratinocytes, the cells showed inhibited growth and low levels of GM3 has 
been linked to various forms of proliferative skin disorders including psoriasis and 
squamous cell carcinomas119,120. GM3 has been targeted as potential therapeutic option 
for treating cancers due to its pro-apoptotic pathways. GM3 has been shown to prevent 
metastasis by disrupting cellular motility and induces apoptosis by interacting with CD82 
and CD9 which are metastasis-suppressing genes121. 
In the CNS, GM3 has also been shown to selectively halt proliferation in dividing 
neural stem cell and astrocytes and promotes apoptosis by acting on cyclin-dependent 
kinase inhibitor, p27122. GM3 has been shown to be particularly abundant in the brains 
during embryonic development20 but is below the threshold of detection in healthy adult 
brains27. However, GM3 levels showed an increase within the infarct region of a brain 
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after mice underwent MCAO treatment as detected by MALDI imaging in situ27. GM3, 
unlike GM1, has been linked to apoptosis of cells. In vitro studies showed that GM3 was 
upregulated in HT22 immortalized mouse hippocampal cells undergoing 
neurodegeneration by glutamate excitotoxicity. When GM3 was also added exogenously 
to these cell lines, increase in neuronal death was observed. Additionally, increasing the 
levels of GM3 by injection of GM3 synthase mRNA in zebra fish embryos resulted in 
increase in cell death123.  
GM3 also has been associated with the pathophysiology of AD in animal models. 
In mutant mice that overexpress GM3 due to GM2 synthase deficiency, there was a 
significant increase in the level of amyloid-β protein plaques deposited in the vascular 
tissues. These mice also showed signs of cerebral amyloid angiopathy, where amyloid-β 
protein extend from the blood vessels into the parenchyma124. 
Another disease associated with GM3 is the Niemann-Pick disease. Common 
signs of this disease are developmental delay, childhood onset of ataxia, vertical 
supranuclear gaze palsy (VSGP) dementia, and seizures125. In this disease there is a built-
up of various sphingolipids and GSL, mainly gangliosides that are stored in the brain. 
Among the gangliosides stored in the lysosomes, GM2 and GM3 are the predominant 
species104. Accumulation of these gangliosides by defective enzymes in the lysosome 
ultimately leads to neurodegeneration126. One group found that activity of sphingosine-1-
phosphate (S1P), an antiapoptotic molecule, was increased by partially deleting the GM3 
synthase gene in the Niemann-Pick Type C brain, suggesting that GM3 synthase 
inactivity can attenuate the pathology of neurodegeneration in Niemann-Pick Type C by 
decreasing the amount of GM3 available in the cells125.  
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At the behavioral level, GM3 seems necessary to maintain normal cognitive 
function. When GM3 was knocked out of mice, they showed lower scores in the Y-maze 
test which is used for assessing cognition levels127. When these mice were administered 
with nicotine, their behavior levels returned to normal, suggesting that GM3 may play a 
role in the nicotinic signaling pathways. At the same time, children who suffered from 
GM3 synthase mutation showed signs of refractory epilepsy, psychomotor delay, 
blindness and deafness128. However, mice that were knocked out of GM2/GD2 synthase, 
which leads to build-up of GM3, showed reduction in weight, abnormal shape of the 
brain, dysfunction in locomotion tests and their fear and emotional behavior was also 
reduced, which all were exacerbated with aging129. 
 
 
1.12 Glutamate Toxicity and Neuronal Death 
 
Glutamate is one of the most ubiquitous excitatory neurotransmitter within the 
brain that is present in millimolar concentrations at the presynaptic terminals at 
physiologically normal conditions in humans130. Despite its abundance in the nervous 
system, abnormal quantities of this excitatory amino acids (EAA) can lead to injurious 
events in the brain131, termed excitotoxicity. Glutamate excitotoxicity is one of the many 
consequences of various insults of the brain, such as traumatic brain injury (TBI), 
hemorrhage, ischemia, AD, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), 
and PD 132–138, leading to degeneration of neurons. In normal conditions, glial cells 
actively uptake the excessive glutamate from the extracellular space before it reaches a 
harmful threshold139.  
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One way in which excess glutamate causes neuronal death is through its ability to 
over-activate the postsynaptic receptors. Once glutamate is released into the synaptic 
cleft, it binds to ionotropic receptors such as N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or kainate receptors140. Once 
excessive quantities of glutamate are released into the synaptic cleft, it over-activates the 
ionotropic receptors and causes abnormally large quantities of Ca2+ to enter the 
neurons141,142.  Although Ca2+ influx is required for normal neuronal function, irreversible 
damage and death may result from excessive amount of Ca2+ entering the cell as this 
activates various enzymes such as proteases, lipases, and nitric oxide synthase (NOS)143. 
NOS activation produces nitric oxide (NO)144,145, which produces oxidative compounds 
that causes nitration and oxidation of proteins, lipid peroxidation, and DNA 
damage146,147. Exposure to glutamate is one of many methods that can be used to induce 
neurodegeneration. 
 
1.13 Rationale 	  
Gangliosides are expressed abundantly in the nervous system and their roles have 
been implicated in brain development, injury and repair. However, the temporal 
expression profile of gangliosides (when and which gangliosides are up and down-
regulated) or the distinct roles these molecules play within dying neurons is yet unclear. 
Therefore, an understanding of the key gangliosides and defining their roles in 
neurodegeneration may provide potential novel targets for therapeutic intervention. 
 Preliminiary evidence suggests that GM2 and GM3 are increased while GM1 is 
decreased in rat and mice models of stroke27,148. What is not clear, however, is whether 
	   24	  
these changes occur in neurons or other cell types within the brain. Therefore, work in 
this thesis sets out to define the temporal expression profile of GM1, GM2 and GM3 
following glutamate toxicity in neurons. Preliminary studies also suggest that GM1 may 
play protective roles in neuronal injury in vivo. Therefore the second component of this 
thesis sets out to determine if GM1 can protect against glutamate toxicity in neurons. We 
believe that there is a balance in the regulation of a-series gangliosides in neurons. As the 
neurons start to die, the expression levels of gangliosides shift to the simple species such 
as GM2 and GM3, leading to a decrease in GM1. By being able to restore the balance by 
pretreating the neurons with exogenous GM1, we believe that the neurons’ membrane 
integrity will be preserved and promote survival during stress induced by glutamate. 
	  
1.14 Hypothesis and Aims 
 
Aim 1: Investigate the expression profile of gangliosides in rat cortical embryonic 
neurons undergoing neurodegeneration by glutamate exposure. 
 
Hypothesis 1:  Ganglioside expression profiles of cortical embryonic neurons will change 
following stress induced by glutamate exposure. Specifically, GM2 and GM3 ganglioside 
expression will increase while GM1 ganglioside expression will decrease over time. 
 
Aim 2: Determine whether exogenous treatment of GM1 can protect neurons from 
undergoing neurodegeneration. 
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Hypothesis 2: Pretreating the rat embryonic cortical neurons with exogenous GM1 prior 
to glutamate exposure will restore the balance in the GM1 loss in the neurons and reduce 
damage and death to the cells exposed to glutamate. 
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Culturing cortical neurons from rat embryo 
 
2.1 Animals 
 
All experimental procedures were carried out aligned with the standards of 
Canadian Council on Animal Care and protocols were approved by Western University 
Animal Use Subcommittee. Pregnant female Wistar Rats (Charles River, Montreal, 
Quebec) were housed at a temperature of 22-24 °C and were provided food and water ad 
libitum. 
 
2.2 Plate Preparation 
 
To coat the plates, 7 % poly-L-Ornithine (molecular weight 30,000-70,000 Sigma, 
St. Louis, MO, USA) solution was prepared with distilled water. Glass cover slips were 
placed in each of the 24-well plates and these were coated with 500 µL of the 7 % poly-
L-Ornithine solution. The 10 cm plates were coated with 10 mL of 7 % poly-L-Ornithine 
solution. All of the plates were incubated with the solution for 1 h at room temperature in 
the bio-hood. The solution was then aspirated and washed three times with distilled 
water. They were left to dry overnight at room temperature. 
 
2.3 Cell Culture 
 
One pregnant female Wistar rat was sacrificed by cervical dislocation. Embryos 
were surgically removed from the female mother on embryonic day 18 (E18). The 
dissected uterus was taken out and was placed in a petri dish containing 10 mL of Hank’s 
balanced salt solution (HBSS, Wisent Bioproducts, St. Bruno, Quebec). Cortices from 
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each embryo were extracted and the meninges were carefully removed with tweezers. 
The cortices were placed in separate petri dish containing HBSS on ice.  
 
Following volumes are for 10 brains: 
Rat embryo brain cortices were placed in a 14 mL conical tube containing 1.8 mL 
of HBSS. The tube was centrifuged at 4000 x g for 1 min at room temperature. HBSS 
was aspirated and 1.8 mL of solution A containing 5 mL HBSS, 6 µL MgSO4 (1 M) and 2 
mL trypsin (Sigma, St. Louis, MO, USA) was added to the same conical tube. The tube 
was mixed well by shaking and rotating by hand, ensuring the neurons were free floating, 
and were rotated at 37 °C for 25 min in an automated rotator in a heated chamber. After 
rotation, 3.6 mL of solution B containing 7 mL HBSS, 8 µL MgSO4 (1 M), 175 µL 
DNase1 (10 mg/mL) (Roche Life Sciences, Indianapolis, IN) and 112 µL trypsin 
inhibitor (100 µg/mL) (Roche Life Sciences, Indianapolis, IN) were added to the conical 
tube and mixed by shaking and rotating by hand for 2 min. The tube was then centrifuged 
at 4000 x g for 5 min at room temperature and HBSS was aspirated. Finally, 6 mL of a 
solution C containing 20 mL of HBSS, 48 µL MgSO4 (1 M), 1.3 mL DNase1 (10 
mg/mL), and 1 mL trypsin inhibitor (100 µg/mL) was added to the resulting cell pellet. 
These cells were transferred to 50 mL falcon tube and another 6 mL of solution C was 
further added. The cells were titrated 10-15 x until the solution appeared homogenous. 
Cells were then centrifuged at 4000 x g for 5 min and the supernatant was aspirated. The 
cell pellet were re-suspended in 36 mL of Neurobasal plating media containing 96 % 
neural basal media (NBM, Wisent Bioproducts, ST. Bruno, Quebec), 2 % B27 
supplement (Invitrogen, Carlsbad, CA), 0.8 % N2 Supplement (Invitrogen, Carlsbad, 
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CA), 0.5 % penicillin/streptomycin (Invitrogen, Carlsbad, CA), 0.25 % Glutamax 
(Invitrogen, Carlsbad, CA), and 0.1 % Amphotericin B solution (Sigma, St. Louis, MO, 
USA). The cell suspension was kept on ice during cell counting. In order to count the 
cells, 20 µL of Trypan Blue Solution (Thermo Fisher Scientific, Waltham, MA, USA) 
and 20 µL of cortical cell suspension were prepared. The cells were counted in the 
following way on the hemacytometer (Thermo Fisher Scientific, Waltham, MA, USA), 
using a cell counter and a microscope:  
Calculation: Cells/mL = Avg. count of 2 squares x dilution factor (2) x 104  
i.e. avg. cells in 2 squares of Hemacytometer= 100 cells 
100 x dilution factor (2) = 200 
200 x 104 = 2 x 106 = 2,000,000 cells/mL 
We have a 36 mL cell suspension, so total we have 7.2 x 107 cells 
 
Using this calculation, media was added to the cortical cell suspension to create a stock 
suspension at 1.0 x 106 cells/mL. The cells were plated at density of 0.5 x 106 cells/well 
by adding 500 µL of the 1.0 x 106 cells/mL solution to the 24-well plates and 1.0 x 107 
cells/plate by adding 10 mL of the 1.0 x 106 cells/mL solution to the 10 cm plates. Cells 
were kept in an incubator at 37 °C and 5 % CO2.  Half of the media was exchanged every 
2 days until 14 days in vitro (DIV). 
 
2.4 GM1 Treatment 
 
GM1 stock solution was made by directly dissolving GM1 (Sigma, St. Louis, 
MO, USA) in NBM to achieve a final concentration of 100 µM. Neurons in the 24-well 
plates were pretreated with 0, 5, 10, 25 µM of GM1 24 h prior to exposure to glutamate.  
 
	   30	  
2.5 Glutamate Exposure 
 
10 mM of stock glutamate solution was made with phosphate-buffered saline 
(PBS). On DIV 14, cells were exposed to 100 µM of glutamate149 for 1, 3, 6, and 24 h for 
24-well plates and 10 cm plates. 10 cm plates were used for lipid extraction and 24-well 
plates were used for immunohistochemistry analysis.  
 
2.6 Cell Fixation & Immunofluorescence  
 
The neurons in the 24-well plates were treated with 20 µL of 1 mg/mL PI solution 
45 min before cell fixation. After these cells were exposed to 100 µM of glutamate for the 
time points, they were fixed with 4 % paraformaldehyde (PFA) for 15 min and washed 
with PBS three times. Cover slips containing neurons were washed with PBS 3 x and 
were incubated with either GM1 (Abcam, Toronto, Ontario) or GM3 (Amsbio, Milton 
Park, Abingdon, UK) at 1:100 diluted with 3 % bovine serum albumin (BSA) in 0.01 M 
PBS for 24 h at 4 °C. Cover slips were washed with PBS 3x and were incubated with 
FITC-conjugated dylight 488 secondary anti-mouse (1:200) (Thermo Fisher Scientific, 
Waltham, MA, USA) for GM3 and FITC-conjugated dylight 488 secondary anti-rabbit 
(1:200) (Thermo Fisher Scientific, Waltham, MA, USA) for GM1 for 24h at 4°C. The 
cover slips were washed with PBS 3 x and double distilled H2O 2 x and were mounted 
onto microscope glass slides with Fluoroshield with 4’,6-diamidino-2-phenylindole 
(DAPI, Sigma, St. Louis, MO, USA). 
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2.7 Lipid Extraction 
 
Lipids were extracted using a modified Folch method150. Four 10 cm plates were 
used to create a single experimental replicate (n=1). Each plate was washed with PBS on 
ice before scraping. Following PBS washing, cells were scraped using a cell scraper and 
collected into a glass tube. To the 0.8 volume parts of aqueous cell extract, 2 parts of 
methanol was added and homogenized using an automated homogenizer. Subsequently, 1 
part of chloroform was added to give one phase Chloroform:Methanol:Water (C:M:W) = 
1:2:0.8. This mixture was left at room temperature for 1 h with periodical vortexing. 1.2 
parts of water was added to the sample for phase separation to achieve a final 
composition of C:M:W = 1:2:2. Sample was centrifuged at 2000 rpm and the upper 
aqueous phase was collected. The lower phase in the glass tube was re-extracted with the 
theoretical upper phase of M:W = 2:2 and was centrifuged at 2000 rpm. The upper phase 
was added to the first extracted sample and KCl was added to achieve a final 
concentration of 0.1 M.  
Prior to eluting the gangliosides using the Solid Phase Extraction C18 column 
(Waters, Mississauga, Ontario), the column was first washed with 10 mL of MeOH, 10 
mL of CHCl3:MeOH (2:1), another 10 mL of MeOH, and 10 mL of MeOH:0.1KCl (1:1). 
Then the upper phase cell extract was passed through the column twice. 20 mL of H2O 
was applied through the column. The sample was eluted with 2 mL of MeOH and 10 mL 
of CHCl3:MeOH (1:1). Sample was evaporated to complete dryness with N2 gas and 
stored in -80 °C until analysis. Before analyzing the sample with the mass spectrometer, 
the dried sample was re-dissolved in 1 mL of CHCl3:MeOH (1:1) and was put in the 
sonicator bath for 15 min.  
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2.8 Electrospray Ionization Mass Spectrometry Detection of Gangliosides 
 
Liquid Chromatography Conditions 
Samples were separated using a Luna 3 µm 100 Å NH2 LC column (150 x 1 mm; 
Phenomenex, Torrance, CA). LC conditions were adapted from Ikeda et al. 2010151. 
Mobile phase constituted of 2 solutions: A) acetonitrile/water (83:17) (1 mM ammonium 
formate) B) acetonitrile/water (1:1) (50 mM ammonium formate). Initial gradient was 
held for 5 min at solution A:B = 100:0, converted linearly to A:B=25:75 for 5 min, then 
converted linearly to A:B=10:90 for 5 min and held there for 10 min. The flow rate was 
set to 0.15 mL/min and the temperature of the column was set to 40 °C.  
Mass spectrometry was performed with Waters QToF Micro (Waters, 
Mississauga, Ontario) and the spectra were analyzed by Mass Lynx v4.1 software 
(Waters). Flight tube voltage was set to 5630 V, MCP voltage was set to 2700 V. Source 
tube voltage was set to 3500 V and the sample cone was set to 40 V and ran on negative 
ion mode. The source temperature was set to 100 °C and desolvation temperature was set 
to 300 °C. Collision energy was set to 5 V. Each experimental replicate was analyzed 
three times to produce three technical replicates.  NaCsI was used to calibrate the 
instrument and GM1 standards from bovine brain were purchased from Avanti Polar 
Lipids (Alabaster, Alabama).  
 
Quantification of Gangliosides 
 
Specific gangliosides of interest were searched in the chromatogram according to 
mass to see at which time points they were eluted. The chromatogram was extracted to 
analyze the mass spectrum of the eluants. The peak intensities of these gangliosides were 
recorded. To quantify these ganglioside species, the peaks were normalized in the 
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following way. Firstly, the peak intensities of all nine gangliosides were summed for a 
single run in one time point. This was done for every run within each time point. Then 
the average of total lipid peak intensities from all of the runs was calculated. In order to 
account for the different amount of lipids that were ran per sample, we calculated the 
quotient between the total lipid peaks relative to the average peak intensity of all runs. 
This number was divided by the peak intensities of each ganglioside peak. Furthermore, 
when neurons are undergoing apoptosis, some cells become detached from the plates and 
are washed away which also adds to the variation in the total lipids present in the sample. 
In order to account for this variation, DAPI cell counts were used to quantify the average 
number of cells present in each experimental settings. A factor was found relative to the 
control, and this number was multiplied to the peaks of each gangliosides as well. 
 
 
 
Example: 
All of the following are intensities from 1 h glutamate exposure groups 
Run 1:  
Ganglioside A – 400, Ganglioside B – 200 Ganglioside C – 600 Ganglioside D- 1000 
Run 2: 
Ganglioside A – 100, Ganglioside B – 50, Ganglioside C – 150, Ganglioside D – 250 
Run3: 
Ganglioside A – 200, Ganglioside B – 100, Ganglioside – C 300, Ganglioside D - 500 
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Total Lipids from Each Run 
Run 1: 400 + 200 + 600 + 1000 = 2200 
Run 2: 100 + 50 + 150 + 250 = 550 
Run 3: 200 + 100 + 300 + 500 = 1100 
Average of Three Runs = (2200 + 550 + 1100)/3 = 1283 
Using this average, we found the quotient factor for each of the runs: 
Run 1: 2200/1283 =1.714 
Run 2: 550/1283 = 0.4286 
Run 3: 1100/1283 = 0.8574 
 
These values would be divided by each of the ganglioside peaks in the appropriate runs 
 
 
 
 
 
 
 
 
 
 
 
 
Run 1  
Ganglioside A – 400/1.714 = 233 
Ganglioside B – 200/1.714 = 117 
Ganglioside C – 600/1.714 = 350 
Ganglioside D – 1000/1.714 = 583 
 
 Run 2  
Ganglioside A – 100/0.4286 = 233 
Ganglioside B – 50/0.4286 = 117 
Ganglioside C – 150/0.4286 = 350 
Ganglioside D – 250/0.4286 = 583 
 
 
Run 3  
Ganglioside A – 200/0.8574 = 233 
Ganglioside B – 100/0.8574 = 117 
Ganglioside C – 300/0.8574 = 350 
Ganglioside D – 500/0.8574 = 583 
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MS/MS Conditions 
 
Ganglioside eluants were collected from the Luna 3 µm 100 Å NH2 LC column 
(150 x 1 mm; Phenomenex, Torrance, CA) using a syringe. The gangliosides in the 
syringe were directly injected into the Orbitrap mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA) for tandem mass spectrometry (MS/MS) analysis. 
Negative ion mode was used and the gangliosides were fragmented using high-energy 
collisional dissociation at voltages ranging from 50 – 75 V. Each gangliosides were 
individually selected based on their specific mass as a precursor molecule. Each of the 
gangliosides were identified by detecting specific fragments: sialic acid, sugar molecules, 
and the ceramide base. 
 
Culturing microglia from neonatal rat  
2.9 Animals 
 
All experimental procedures were carried out aligned with the standards of 
Canadian Council on Animal Care and protocols were approved by Western University 
Animal Use Subcommittee. Postnatal day 0-2 neonatal Wistar Rats (Charles River, 
Montreal, Quebec) were housed at a temperature of 22-24 °C and were provided food and 
water ad libitum. 
 
2.10 Plate Preparation 
 
To coat the T75 culture flask (Corning, Tewksbury, MA, USA), 5 µg/mL of Poly-
D-Lysine (EMD Millipore, Billerica, MA, USA) solution was prepared with autoclaved 
water. The T75 plates were incubated with the Poly-D-Lysine solution for 3 h at 37 °C. 
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The Poly-D-Lysine solution was aspirated and the plates were washed once with 
autoclaved water. The plates were dried under UV light in the cell culture hood for 20 
min. The plates were prepared just prior to the dissection process. 
 
 
 
2.11 Cell Culture 
 
Postnatal day 0-2 neonatal (P0-2) Wistar rat was sacrificed by hypothermia. The 
head was wiped with 70 % ethanol and Kimwipe (Kimberly-Clark Professional, Roswell, 
GA, USA). The head was removed with scissors and 4 pups were used per T75 culture 
flask (Corning, Tewksbury, MA, USA). The heads were placed in petri dish that 
contained ice-cold HBSS (Wisent Bioproducts, St. Bruno, Quebec). After removing the 
skin and the skull with forceps, the brain was removed with a spatula and placed in a 
fresh petri dish containing ice-cold HBSS. Using microforceps and dissection 
microscope, the cortex was isolated and the meninges were removed. These cortices were 
placed into 15 mL conical tubes with 14 mL of ice-cold HBSS on ice. HBSS was 
aspirated from the conical tubes containing the 4 brains and 4 mL of 1 x 
trypsin/ethylenediaminetetraacetic acid (EDTA) solution (Fisher Scientific Company, 
Ottawa, Ontario) was added to the conical tube. The brain tissue was titrated with p1000 
pipette tip and the tube was incubated for 15 min at 37 °C. To stop the enzymatic 
digestion, 4 mL of complete microglial media made from 1 x Dulbecco’s Modified Eagle 
Medium (DMEM, Wisent Bioproducts, St. Bruno, Quebec), 10 % fetal bovine serum 
(Fisher Scientific Company, Ottawa, Ontario), 1 % sodium pyruvate (Cellgro®Corning, 
Tewksbury, MA, USA), 0.08 % gentamycin (BioWhittaker®, VWR International, 
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Radnor, PA, USA) was added to the conical tube containing the brain tissue. The tube 
was shaken by hand to mix the contents and was spun at 1500 rpm for 5 min. The 
supernatant was aspirated and 4 mL of complete microglial media was added into the 
tube. The content in the tube was mixed again by mixing by hand and was centrifuged at 
1500 rpm for 5 min. After aspirating the supernatant, the cells were resuspended in 10 
mL of complete microglial media and filtered through a 40 µM mesh cell strainer 
(Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA). The cells were 
plated at density of 8 cortices per 10 mL of total microglial media in the T75 culture flask 
(Fisher Scientific Company, Ottawa, Ontario). The T75 culture flask was then incubated 
at 37 °C and 5 % CO2. On day 3 of incubation, the media was exchanged with complete 
microglial media. On day 10, in order to detach the microglia, 400 µL of 60 mM 
lidocaine (Sigma, St. Louis, MO, USA) in HBSS was directly added into the T75 culture 
flask. The T75 culture flask was then incubated at room temperature for 10 – 15 min. The 
detached microglia in the T75 flask was collected in a falcon tube and the plate was 
washed with HBSS and the remaining microglia was collected in the same falcon tube. 
To the cell suspension in the falcon tube, 5 mM of  EDTA (pH 8.0) was added to a final 
concentration of 50 µM. The falcon tube with the cell suspension was spun in the 
centrifuge at 15000 rpm for 5 min and re-suspended in 1 mL of DMEM with 1 % fetal 
bovine serum. Using a hemacytometer, a cell counter, and a microscope, viable cells 
were counted:  
Calculation: Cells/mL = Avg. count of 2 squares x dilution factor (2) x 104  
i.e. avg. cells in 2 squares of Hemacytometer= 100 cells 
100 x dilution factor (2) = 200 
200 x 104 = 2 x 106 = 2,000,000 cells/mL 
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The microglia suspension was split and placed into 24-well plates with glass cover slips 
coated with 5 µg/mL of Poly-D-Lysine (EMD Millipore, Billerica, MA, USA) at density 
of 2.5 x 104 cells per well. The 24-well plates with the microglia were kept in the 
incubator at 37 °C and 5 % CO2. 
 
2.12 Amyloid β 1-42 Oligomer Preparation for Microglia 
 
Amyloid β-Protein (1-42) (Aβ peptide) was purchased from Bachem Americas, 
Inc. (Torrance, CA, USA) and was stored in -80 °C in a vial. When they were ready for 
use, Aβ peptide was equilibrated to room temperature for 10-15 minutes. Prior to re-
suspending the Aβ peptide in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) (Sigma, St. 
Louis, MO, USA), HFIP was placed on ice in the fume hood to cool. After HFIP was 
cooled, it was added to the vial containing solid Aβ peptide to achieve a final peptide 
concentration of 1mM. The vial was vortexed thoroughly. The peptide solution in the vial 
with HFIP was placed in room temperature until the peptide was completely dissolved. 
The vial containing the Aβ peptide solution was then placed onto ice for 10 min. Once 
the Aβ peptide solution in the vial was cooled, 10 µL was aliquoted into 0.5 mL 
microcentrifuge tubes. Parafilm was placed over the tubes containing the aliquoted Aβ 
peptide solution and holes were made with 27 G needle. The solution in the tubes were 
then lyophilized for 60 min until all traces of HFIP was removed and the resulting 
peptide appeared as a thin and clear film at the bottom of the tube. The dried Aβ peptide 
film was stored in -80 °C until use. 
Dried Aβ peptide film was removed from -80 °C and placed on ice. 10 µL of fresh 
anhydrous dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, USA) was added into the 
	   39	  
microcentrifuge tubes containing the dried Aβ peptide. The DMSO/Aβ peptide solution 
was pipetted thoroughly to dissolve the Aβ peptide. The microcentrifuge tube containing 
the DMSO/Aβ peptide was then sonicated for 10 min at 37 °C. PBS added to the tubes to 
achieve a final DMSO/Aβ peptide concentration of 150 µM and the peptide was 
oligomerized by incubating for 24 h at 4 °C. This oligomer preparation was stored in -80 
°C until use. 
 
 
2.13 Aβ Toxicity on Microglia 
 
On DIV 2, microglia were adhered to the glass coverslips and ready for exposure 
to Aβ oligomer. The microcentrifuge tube containing Aβ oligomer preparation was 
removed and placed at room temperature. From the microcentrifuge, 6.76 µL of Aβ 
oligomer preparation was added into the 24-well plates to achieve a final concentration of 
2 µM of Aβ oligomer. Microglia were incubated with 2 µM of Aβ oligomer for 1 h to 
activate them.  
 
 
2.14 Microglia Fixation & Immunofluorescence  
 
After the cells on the coverslips were exposed to Aβ peptide, 500 µL of 4 % PFA 
was directly added into each of the 24 wells containing the media. After 2 min, 4 % PFA 
was removed and replaced with 2 % PFA and the cells on the coversliips were incubated 
for 20 min at room temperature. The coverslips were washed with PBS 3 x and were 
placed in the fridge at 4 °C until staining. Cover slips containing the microglia were 
washed with PBS 3 x and were incubated with either GM1 (Abcam, Toronto, Ontario) or 
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GM3 (Amsbio, Milton Park, Abingdon, UK) at 1:100 diluted with 3 % BSA in 0.01 M 
PBS for 24 h at 4 °C. Cover slips were washed with PBS 3 x and were incubated with 
FITC-conjugated dylight 488 secondary anti-mouse (1:200) (Thermo Fisher Scientific, 
Waltham, MA, USA) for GM3 and FITC-conjugated dylight 488 secondary anti-rabbit 
(1:200) (Thermo Fisher Scientific, Waltham, MA, USA) for GM1 for 24h at 4°C. 
Activated microglia that were also labeled with GM3 and FITC were also co-labelled 
with 1:100 glial fibrillary acidic protein (GFAP, Thermo Fisher Scientific, Waltham, 
MA, USA) with 3% BSA in 0.01 M PBS for 24 h. The cover slip was then washed with 
PBS 3 x and incubated with Alexa 594 (Thermo Fisher Scientific, Waltham, MA, USA) 
(1:200) secondary anti-rabbit for 24 h. The cover slips were washed with PBS 3 x and 
double distilled H2O 2 x and were mounted onto microscope glass slides with 
Fluoroshield with DAPI (Sigma, St. Louis, MO, USA).  
 
2.15 Imaging 
 
Images were taken on Nikon Eclipse Ni (Nikon Instruments Inc, Melville, NY, 
USA) microscope. Analysis and quantification was done using ImageJ (Wayne 
Rasband, National Institute of Health, Bethesda, USA) 
 
Cortical Neurons: 
 
A single cover slip was used to create a single experimental replicate (n=1) and 
three pictures from different regions of the cover slip were taken for triple technical 
replicates. In order to quantify the number of viable neurons that expressed GM1 at each 
time point of glutamate exposure, ImageJ (Wayne Rasband, National Institute of Health, 
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Bethesda, USA) was first used to merge the DAPI, PI and GM1 images. Then, the 
number of neurons that were positive for GM1 without PI positive nuclei was counted 
using Image J. This number was divided by the total cell counts based on DAPI and 
expressed as a percentage of total neurons. The percentage of neurons that express GM1 
without PI nuclei from each time point of glutamate exposure was normalized to the 
control value.  
 
To assess the level of neuronal viability, the total number of PI positive neurons 
within each picture was expressed as a percentage of total number of neurons present 
within the picture. The percentage of PI positive cells from three replicates gave an 
average of PI positive cells per n. This calculation was used to assess the level 
neuroprotective property of GM1 ganglioside in glutamate exposure.  
 
DAPI images at 40 x was taken and stitched together using the Nikon Imaging 
Software Elements (Nikon). On ImageJ, using a grid setting of 500000 pixels per area, 
five random squares were chosen. Within each of these squares, the total number of 
DAPI positive cells were counted and averaged to represent the total number of cells 
present within the time frame. This was done for each glutamate exposure time points to 
account for the number of cells present for each time point. 
 
Primary Microglia:  
 
GM1 and GM3 optical densitometry on control (non-activated) and activated 
microglia was performed using ImageJ (Wayne Rasband, National Institute of Health, 
Bethesda, USA).  
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2.16 Data Analysis 
 
Averages of all data were calculated using Microsoft Excel. Statistical analysis 
was performed using Prism 6 (GraphPad). Multiple group comparisons were done by 
one-way ANOVA. Comparison of the intensity of different carbon chain ganglioside was 
done by two-way ANOVA. Statistical significance was done to compare experimental 
groups to the control groups using Dunn’s and Dunnett’s multiple comparisons post hoc 
test. To test the significance between two groups, Tukey’s multiple comparison test was 
performed. Data is presented as mean ± SEM. All significance level was set to p ≤ 0.05. 
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Section 3: RESULTS 	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3.1 Effects of glutamate exposure on cortical neurons 
 
Glutamate has been previously shown to induce neuronal cell death152. It was 
nevertheless important for us to confirm whether glutamate was a viable method to 
induce neuronal death in our primary cell system. Jong et al149. used varying 
concentration of glutamate, from 10 µM to 2 mM and determined that 100 µM was an 
optimal dose to induce gradual neuronal death. Thus, this would permit us to track the 
possibility of gradual changes of ganglioside expression profiles in dying neurons. For 
this study, DIV 14 embryonic rat cortical neurons were exposed to 100 µM of glutamate 
for up to 24 h. These neurons were also labeled with PI 45 min before fixation with PFA 
to assess the level of dying neurons. 
Healthy control neurons that were not exposed to glutamate (control) showed 
round cell bodies with discernible projections protruding out to the periphery. These cells 
were not accompanied by PI signal in the nucleus (Fig. 5 A). As early as 1 h following 
glutamate exposure, neuronal projections began to retract. At this stage, neurons showed 
uptake of PI into the nucleus indicating dying neurons (Fig. 5 A). By 3 h of glutamate 
exposure, there was a visible increase in the number of PI positive neurons. Following 6 
h of glutamate exposure, the structural integrity of neurons was severely compromised 
and showed high levels of PI in the nuclei. By 24 h, levels of neuronal death were 
extensive as indicated by the cell debris as well as PI positive nuclei.  
Neuronal viability was quantified by subtracting the number of PI positive 
neurons from total neuron cell counts using DAPI and expressed as a percentage of total 
cells. The percentage of living cells was then normalized to the controls (100 % ± 1.712). 
As early as 1 h following glutamate exposure, neurons showed a significant decrease (1 
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h: 71.1 ± 2.0 %) in viability compared to uninjured controls (Fig. 5 B, p ≤ 0.05). By 3 h 
of glutamate exposure, neuronal viability decreased significantly (3 h: 33.5 ± 4.0 %) and 
remained significantly reduced by 6 and 24 h compared to controls (6 h: 20.6 ± 3.9 %, 24 
h: 26.8 ± 8.1 %) (Fig. 5 B, p ≤ 0.05). 
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Figure 5. Quantification of viable cells after exposure to glutamate. (A) 
Photomicrograph of DIV 14 rat cortical neurons following exposure to 100 µM glutamate.  
Neurons were exposed to 100 µM of glutamate for 1, 3, 6, or 24 h and fixed with 4 % 
PFA. These cells were labeled with DAPI and PI. (B) The number of PI positive neurons 
were subtracted from the total DAPI counts to assess the number of viable neurons. The 
number of viable neurons was divided by the total cell counts based on DAPI and 
expressed as a percentage of total cells. Data is normalized to the control. Data is 
presented as mean +/- SEM; data was analyzed and compared to the control by one-way 
ANOVA and Dunnett’s multiple comparisons test. * indicate p ≤ 0.05 (n=8 for reach time 
point). Bar indicates 50 µm for each panel. 
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3.2 Ganglioside GM1, GM2, and GM3 Levels in Neurons Exposed to Glutamate 
 
 To investigate the changes of ganglioside GM1, GM2, and GM3 levels in neurons 
following exposure to glutamate, lipids were extracted using a modified Folch method150. 
These cell lipid extracts were collected and filtered through a solid phase extraction C18 
column and NH2 hydrophilic column and analyzed through a Waters QTOF Micro mass 
spectrometer and Mass Lynx 4.1 (Fig. 6, 8, 10). The d16:1, d18:1, and d20:1 sphingosine 
moieties of gangliosides were analyzed as they are believed to play different roles with 
respect to neuronal function and death153,154. In order to account for varying amount of 
lipids collected from different cell replicates, the peaks of each gangliosides were 
normalized to the sum of 9 lipid species of interest (d16:1, d18:1, and d20:1 for GM1, 
GM2, and GM3). To further adjust for the total starting lipid present in the sample, a 
numerical factor was found between the total number of neurons present in the 10 cm 
plate of each time point of glutamate exposure relative to the control 10 cm plates. This 
was done by dividing the number of neurons present in the coverslips of control group by 
the number of neurons present in the cover slips from each time points of glutamate 
exposure. The factors for each time point was multiplied to the ganglioside peaks for the 
corresponding time of glutamate exposure (Fig. 7 D). This process took into account of 
the neurons that died and detach from the plates, which resulted in reduced levels of 
starting lipids. 
 At 1 h following glutamate exposure, d16:1 GM1 did not show a significant 
change compared to control levels (Control: 100 ± 2.4 %, 1 h: 88.6 ± 7.8 %) (Fig. 7 A, p 
> 0.05). However, following 3 h of glutamate exposure, there was a significant increase 
(3 h: 135 ± 2.7 %) in the d16:1 GM1 compared to control neurons (Fig. 7 A, p ≤ 0.05). At 
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6 h, d16:1 was significantly elevated (6 h: 145.4 ± 4.5 %) (p ≤ 0.05). However, at 24 h, 
there was no significant difference in the level of d16:1 compared to control group (p > 
0.05). When d18:1 GM1 ganglioside level was analyzed in dying neurons, there was no 
significant change at 1 h and 3 h of glutamate exposure compared to control neurons (Fig. 
7 B, p > 0.05). However, there was a significant increase of d18:1 GM1 ganglioside (6h: 
149.8 ± 6.8 %) at 6 h of glutamate exposure compared to the controls (p ≤ 0.05). 
Following 24 h of glutamate exposure, d18:1 GM1 returned to control levels and there 
was no significant difference between the two groups (p > 0.05). Finally, when d20:1 
GM1 was analyzed, there was no significant change between control at any time of 
exposure to glutamate (Fig. 7 C, p > 0.05).  
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Figure 6. Mass spectra of GM1 ganglioside from uninjured control neurons. 
Following the detection of gangliosides with a Waters QTOF ESI-MS instrument, 
chromatogram was extracted with Mass Lynx 4.1 to visualize GM1, GM2, GM3 and its 
d16:1, d18:1, and d20:1 sphingosine moieties. Peaks of GM1, GM2 and GM3 are 
presented relative to each species (A). Higher peaks indicate higher quantity of 
gangliosides. (B) represents an enlarged spectrum of GM1 d18:1 and GM1 d20:1. (C) 
represents an enlarged spectrum of GM1 d16:1. 
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Exposure time to 100 µM glutamate 
Figure 7. GM1 expression changes in rat embryonic cortical neurons exposed to 
glutamate. Normalized peak intensity from Waters QTOF ESI-MS instrument of (A) GM1 
d16:1, (B) GM1 d18:1, and (C) GM1 d20:1 from DIV14 rat cortical neurons following 
exposure to 100 µM of glutamate for up to 24 h. Neurons were cultured in 10 cm plates and 
were exposed to glutamate for 1, 3, 6, and 24 h. Lipids were collected using a modified 
Folch method. Each biological replicate (n) was represented by four 10 cm plates and each n 
was analyzed with a Waters QTOF instrument in triplicates. Peak intensities from each run 
were normalized to the sum of d16:1, d18:1, and d20:1 sphingosine moieties of each GM1, 
GM2, GM3 gangliosides for total of 9 lipids from all the runs within glutamate exposure 
time point. Peaks were multiplied by a cell total number factor for each time point relative to 
control to account for the total number of cells present at different time points of glutamate 
exposure (D). Data is presented as mean +/- SEM; data was analyzed and compared to the 
control by one-way ANOVA and Dunnett’s multiple comparisons test. * indicate p ≤ 0.05. 
(for each time point n = 4).  
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   None of the sphingosine moieties, d16:1, d18:1, or d20:1, of GM2 ganglioside 
showed significant changes throughout the time course of exposure to glutamate 
compared to uninjured control neurons (Fig. 9, p > 0.05). Similarly, none of the 
sphingosine moieties of GM3 gangliosides showed significant changes throughout the 
time course of exposure to glutamate compared to uninjured control neurons (Fig. 11, p > 
0.05).  	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Figure 8. Mass spectra of GM2 ganglioside from uninjured control neurons. Following 
the detection of gangliosides with a Waters QTOF ESI-MS instrument, chromatogram was 
extracted with Mass Lynx 4.1 to visualize GM1, GM2, GM3 and its d16:1, d18:1, and d20:1 
sphingosine moieties. Peaks of GM1, GM2 and GM3 are presented relative to each species 
(A). Higher peaks indicate higher quantity of gangliosides. (B) represents an enlarged 
spectrum of GM2 d16:1, GM2 d18:1 and GM2 d20:1. 
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Figure	  9.	  GM2	  expression	  changes	  in	  cortical	  neurons	  exposed	  to	  glutamate.	  Normalized	  peak	  intensity	  from	  Waters	  QTOF	  ESI-­‐MS	  instrument	  of	  (A)	  GM2	  d16:1,	  (B)	  GM2	  d18:1,	  and	  
(C)	  GM2	  d20:1	  from	  DIV14	  rat	  cortical	  neurons	  following	  exposure	  to	  100	  μM	  of	  glutamate	  for	  up	  to	  24	  h.	  Neurons	  were	  cultured	  in	  10	  cm	  plates	  and	  were	  exposed	  to	  glutamate	  for	  1,	  3,	  6,	  and	  24	  h.	  Lipids	  were	  collected	  using	  a	  modified	  Folch	  method.	  Each	  biological	  replicate	  (n)	  was	   represented	   by	   four	   10	   cm	   plates	   and	   each	   n	   was	   analyzed	   with	   a	   Waters	   QTOF	  instrument	  in	  triplicates.	  Peak	  intensities	  from	  each	  run	  were	  normalized	  to	  the	  sum	  of	  d16:1,	  d18:1,	   and	   d20:1	   sphingosine	   moieties	   of	   each	   GM1,	   GM2,	   GM3	   gangliosides	   for	   total	   of	   9	  lipids	  from	  all	  the	  runs	  within	  glutamate	  exposure	  time	  point.	  Peaks	  were	  multiplied	  by	  a	  cell	  total	  number	  factor	  for	  each	  time	  point	  relative	  to	  control	  to	  account	  for	  the	  total	  number	  of	  cells	  present	  at	  different	  time	  points	  of	  glutamate	  exposure	  (D).	  Data	  is	  presented	  as	  mean	  +/-­‐	  SEM;	   data	   was	   analyzed	   and	   compared	   to	   the	   control	   by	   one-­‐way	   ANOVA	   and	   Dunnett’s	  multiple	  comparisons	  test.	  *	  indicate	  p	  ≤	  0.05.	  (for	  each	  time	  point	  n	  =	  4).	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Figure 10. Mass spectra of GM3 ganglioside from uninjured control neurons. 
Following the detection of gangliosides with a Waters QTOF ESI-MS instrument, 
chromatogram was extracted from Mass Lynx 4.1 to visualize GM1, GM2, GM3 and its 
d16:1, d18:1, and d20:1 sphingosine moieties. Peaks of GM1, GM2 and GM3 are 
presented relative to each species (A). Higher peaks indicate higher quantity of 
gangliosides. (B) represents an enlarged spectrum of GM3 d16:1, GM3 d18:1, and GM3 
d20:1.  
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Figure 11. GM3 expression changes in cortical neurons exposed to glutamate. Normalized peak 
intensity from Waters QTOF ESI-MS instrument of (A) GM3 d16:1, (B) GM3 d18:1, and (C) GM3 
d20:1 from DIV14 rat cortical neurons following exposure to 100 µM of glutamate for up to 24 h. 
Neurons were cultured in 10 cm plates and were exposed glutamate for 1, 3, 6, and 24 h. Their lipids 
were collected using a modified Folch method. Each biological replicate (n) was represented by four 
10 cm plates and each n was analyzed with Waters QTOF instrument in triplicates. Peak intensities 
from each run were normalized to the sum of d16:1, d18:1, and d20:1 sphingosine moieties of each 
GM1, GM2, GM3 gangliosides for total of 9 lipids from all the runs within glutamate exposure time 
point. Peaks were multiplied by a cell total number factor for each time point relative to control to 
account for the total number of cells present at different time points of glutamate exposure (D). Data 
is presented as mean +/- SEM; data was analyzed and compared to the control by one-way ANOVA 
and Dunnett’s multiple comparisons test. * indicate p ≤ 0.05. (for each time point n = 4).  	  
A	   B	  
C	   D	   exposure 
	   58	  
Ganglioside GM1, GM2 and GM3 sphingosine moieties d16:1, d18:1 and d20:1 
are believed to play unique roles in neurons33. Comparing the level of these moieties 
between embryonic neurons and adult neurons may give as an insight to their specific 
roles in neuronal regulation and death. In primary cortical neurons, d18:1 sphingosine 
moieties were the most abundant species of GM1, GM2, and GM3 (Fig. 12) while d16:1 
and d20:1 were less abundant. The difference in the quantity between d16:1 and d20:1 for 
GM1, GM2, and GM3 was not significant in cortical embryonic neurons (p > 0.05). 
However, in 4-month old healthy rat cortices, there was an increased expression of d20:1 
GM1 ganglioside which was significantly higher (d20:1: 695.6 ± 347.8) than d16:1 GM1 
ganglioside (158.0 ± 79.0) (Fig. 12 A, p ≤ 0.05). Furthermore, d18:1 GM2 species in 4-
month old healthy rat cortices was significantly lower (591.8 ± 295.9) than in  control 
(3383.4 ± 1691.7) or glutamate exposed embryonic primary cortical neurons (1 h: 2161.3 
± 1080.6, 3 h: 3786.0 ± 1893.0, 6 h: 4433.4 ± 2216.7, 24 h: 5036.2 ± 2518.1) (Fig.11 B, p 
≤ 0.05). However, there was no significant difference in the expression levels of d18:1 
GM3 gangliosides between control or glutamate exposed primary embryonic cortical 
neurons and 4-month healthy rat brains (Fig. 12 C, p > 0.05). 
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Figure 12. Comparison of peak intensities of sphingosine moieties of gangliosides GM1, 
GM2, and GM3. Peak intensity of (A) GM1, (B)GM2, and (C) GM3 and its d16:1, d18:1, and 
d20:1 moieties from rat adult and embryonic cortical neurons following exposure to 100 µM 
glutamate for up to 24 h. Neurons were cultured in 10 cm plates and were exposed to glutamate 
for 1, 3, 6, and 24 h. Lipids were collected using a modified Folch method. Each biological 
replicate (n) was represented by four 10 cm plates and each n was analyzed with Waters QTOF 
instrument in triplicates. Peak intensities from each run were normalized to the sum of d16:1, 
d18:1, and d20:1 sphingosine moieties of each GM1, GM2, GM3 gangliosides for total of 9 
lipids from all the runs within glutamate exposure time point. Furthermore, the peaks were 
multiplied by a cell total number factor for each time point relative to control to account for the 
total number of cells present at different time points of glutamate exposure (D). Data is 
presented as mean +/- SEM; data presented as mean +/- SEM; data were analyzed and the d16:1, 
d18:1, d20:1 sphingosine moieties were compared by two-way ANOVA and tukey’s multiple 
comparisons test. Data of (D) was analyzed by one-way ANOVA and Dunnett’s multiple 
comparisons test. . * indicate p ≤ 0.05. (for each time point n = 4).  
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3.3 GM1 and GM3 immunohistochemistry 
 
 In order to visualize the expression profile of GM1 ganglioside in dying neurons, 
cortical neurons were labeled with GM1 antibody following exposure to glutamate. These 
cells were also labeled with PI to understand the relationship between the time profile of 
neurodegeneration and GM1 expression.  
 In control neurons, there were only a few PI positive cells and only some neurons 
showed GM1 positive label, which was localized to the cell bodies (Fig. 13 A). By 1 h of 
glutamate exposure, there was an increase in the level of PI positive neurons. At this time 
point, some neurons showed GM1 expression without PI label in the nuclei. By 3 h of 
glutamate exposure, there was a detectable increase in the level of GM1 expressing 
neurons and an increase in PI positive nuclei. There was also an increase in the number of 
neurons that were positive for GM1 and negative for PI. By 6 h, GM1 was highly 
expressed in the neurons. Neurons positive for GM1 and negative for PI were also 
increased by 6 h. However, by 24 h, although there was an increased level of PI positive 
cells, the level of GM1 positive neurons was reduced. There was a reduction and the 
neurons that were positive for GM1 and negative for PI, presumably due to extensive cell 
death by this time point. 
 The number of viable neurons that express GM1 was quantified by dividing the 
number of neurons that were labeled GM1 positive without PI from total number of 
neuron counts by DAPI, and expressing it as a percentage of total neurons. By 1 h of 
glutamate exposure, there was no significant change in the number of neurons that were 
GM positive and PI negative compared to the control group (Fig. 13 B). However, by 3 h 
and 6 h following exposure to glutamate, there was a significant increase in the number 
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of GM1 positive and PI negative neurons compared to the control group, with a peak at 6 
h (control: 100.0 ± 20.5 %, 3 h: 220.1 ± 9.4 %, 6 h: 272.0 ± 38.1 %). By 24 h of 
glutamate exposure, the number of GM1 positive and PI negative neurons decreased back 
down to control levels (p > 0.05). 
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Figure 13. Quantification of viable neurons that express GM1 after exposure to 
glutamate. (A) Photomicrograph of DIV 14 rat cortical neurons following exposure to 100 
µM glutamate.  Neurons were exposed to 100 µM of glutamate for 1, 3, 6, or 24 h and fixed 
with 4 % PFA. These cells were labeled with GM1, DAPI and PI. Arrows indicate neurons 
that are GM1 positive and PI negative. (B) The number of GM1 positive neurons that were PI 
negative were divided by total cell counts based on DAPI expressed as a percentage of total 
cells. Data is normalized to the control. Data is presented as mean +/- SEM; data was 
analyzed and compared to the control by one-way ANOVA and Dunnett’s multiple 
comparisons test. * indicate p ≤ 0.05 (n=8 for reach time point). Bar indicates 50 µm for each 
panel. 	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   To analyze the structural and temporal expression profile of GM3 in neurons 
undergoing neurodegeneration, primary cortical neurons were exposed to glutamate for 1, 
3, 6, and 24 h and fixed with PFA. They were then stained for GM3 ganglioside, DAPI 
and PI.  
 As the exposure time to glutamate increased, neurons lost their structural 
integrity; showed neurite retractions, cell bodies lost their round healthy shape (Fig. 14 
C). This was also accompanied by an increase in PI uptake in the nuclei (Fig. 14 A). 
However, GM3 ganglioside by immunofluorescence was undetectable in either the 
uninjured control cortical neurons or the neurons exposed to glutamate (Fig. 14 A).  
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Figure 14. Photomicrographs of rat embryonic cortical neurons labeled with antibody to GM3, DAPI, 
and PI following exposure to 100 µM of glutamate for up to 24 h. (A) Neurons were exposed to 100 µM of 
glutamate for 1, 3, 6, 24 h. These cells were fixed with 4 % PFA and stained with GM3 antibody, DAPI and 
PI. (B) Zoomed in DIC images of uninjured control neuron and (C) Zoomed in DIC images of neurons 
exposed to 3 h of 100 µM glutamate. Bar indicates 50 µm for each panel.  	  	  	  
Control 
50 µm 
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3.4 Effect of exogenous GM1 pretreatment of rat primary cortical neurons before 
exposure to glutamate  	  
	   In order to assess whether exogenous GM1 pretreatment can provide 
neuroprotection to cortical neurons undergoing neurodegeneration, DIV 14 rat primary 
cortical neurons were treated with 5, 10, or 25 µM of GM1, 24 h prior to 100 µM 
glutamate exposure. These cells were also labeled with PI to assess the level of neuronal 
death. 
 Neurons without exposure to glutamate showed negligible levels of PI positive 
nuclei across different concentrations of GM1 pretreatment (Fig. 15 A). As the time of 
exposure to glutamate increased, there was an increase in PI positive nuclei across all 
groups. However, the neurons that were not pretreated with GM1 showed higher levels of 
PI positive nuclei (Fig. 15 A). By 24 h of glutamate exposure, virtually all cell nuclei 
were positively labeled for PI across all GM1 treatment groups.  
 Cell viability was quantified by subtracting the number of PI positive cells from 
total neuron cell counts using DAPI and expressed as a percentage of total cells. Viability 
values of neurons exposed to various times of glutamate were normalized to the GM1 
pretreated neurons that were not exposed to glutamate. At 1 h of glutamate exposure, 
there was no significant difference in the number of viable neurons across the different 
GM1 treatment concentration groups (Fig. 15 B, p > 0.05). By 3 h of glutamate exposure, 
the neurons that were pretreated with GM1 showed significant increase of neuronal 
viability compared to neurons that were not pretreated with GM1 (no GM1: 33.5 ± 4.0 %, 
5 µM: 68.8 ± 5.4 %, 10 µM: 56.7 ± 4.1 %, 25 µM: 90.2 ± 2.4 %) (Fig. 15 B, p ≤ 0.05). 
Pretreatment with 25 µL showed the greatest number of surviving neurons compared to 
the controls. Following 6 h of glutamate exposure, neurons that were treated with GM1 
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continued to show significant increase in neuronal viability (no GM1: 20.6 ± 3.9 %, 5 µM 
55.8  ± 1.5 %, 10 µM 57.0 ± 4.5 %, 25 µM 72.5 ± 3.7 %) (Fig. 15 B, p ≤ 0.05), with 25 
µM of GM1 showing the greatest survival. By 24 h, there was no significant difference in 
viable neurons across all groups (p > 0.05).  
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Figure 15. Effects of GM1 pretreatment on neurons exposed to 100 µM of 
glutamate. Cortical neurons were treated with 5, 10, or 25 µM of exogenous GM1 
24 h before exposure to 100 µM glutamate. Following exposure to glutamate, 
neurons were fixed with 4% PFA and mounted onto cover slips and stained with 
DAPI (A). Total cell counts were measured using DAPI and PI positive cells were 
used to indicate dying neurons. To quantify cellular viability, neurons that were PI 
negative were expressed as a percentage over all neurons. Data was normalized to 
neurons that were not exposed to glutamate (B). Results are presented as mean +/- 
SEM; data were analyzed and compared to the control (control n=8, GM1 
pretreatment group n = 4) by two-way ANOVA and tukey’s multiple comparisons 
test. * indicate p ≤ 0.05. Bar indicates 50 µm for each panel. 	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3.5 Ganglioside GM1 and GM3 expression pattern in activated microglia 	  	   Microglia are involved in the initial phase of inflammation in the brain and may 
contribute to the ganglioside expression profiles observed in in vivo and in situ models of 
neurodegeneration27. Therefore, it was important to assess the ganglioside expression 
profiles solely in microglia in this study. 
 Primary rat microglia were cultured and on DIV2, they were activated by 
exposing them to amyloid beta oligomers for up to 1 h155–158. They were fixed with 4 % 
PFA and labeled with DAPI and antibody to GM1 or GM3. 
 Control microglia showed small and elongated cell bodies with projections and 
showed weak staining for GM3 (Fig. 16 A, B). When these cells were exposed to 
amyloid beta oligomer for 1 h, a known activator of microglia, they became activated, as 
indicated by spherical and phagocytic appearance (Fig. 16 C). They were also 
accompanied by GM3 staining that showed a punctate pattern within the cell bodies (Fig. 
16 A). When optical densitometry for GM3 expression was performed on control and 
activated microglia, there was a significant increase in the pixel intensity (24.3  ± 5.0 %) 
for GM3 in activated microglia compared to control (Fig. 16 E, p ≤ 0.05). Additionally, 
some coverslips exposed to amyloid beta oligomers were also labeled with GFAP (red) to 
ensure that the source of GM3 expression increase was due to activated microglia and not 
astrocytes. Although some GM3 expression were seen on astrocytes (red), most of the 
GM3 stain does not co-label with GFAP staining, indicating that most of GM3 increase 
observed in these cultures stemmed from microglia (Fig. 16 D). 
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Figure 16.  GM3 expression measured in microglia after being activated with amyloid β oligomer 
for 1 h. Microglia was activated using 2 µM of amyloid β oligomer and fixed with 4 % PFA and 
labeled with DAPI, and GM3 (A). Zoomed DIC image of inactive microglia (B). Zoomed DIC image 
of micoglia after exposure to 2µM of amyloid-β peptide for 1 h (C). Cover slips were also stained with 
GFAP after exposure to 2 µM of amyloid β oligomer (D red). Arrows indicate astrocytes. Pixel 
intensity of GM3 expression per microglia was measured using Image J (E). Average pixel intensity 
per cell of GM3 in microglia after 1 h of exposure to 2 µM of amyloid β oligomer was compared to 
control. Intensity was measured for up to 54 microglia in control and 46 microglia in 1 h of amyloid β 
oligomer exposure across 4 cover slips for each group(n=4). Results are presented as mean +/- SEM; 
data was analyzed by two-tailed t-test. * indicate p ≤ 0.05. Bar indicates 50 µm for each panel. 
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When GM1 staining was analyzed, control microglia showed positive GM1 
staining within the cell body (Fig. 17 A). Once microglia were activated, GM1 expression 
was spread over the entire cell body which took on a round and phagocytic shape. When 
the optical density for GM1 was measured using Image J, there was no significant 
difference between the control and activated microglia (Fig. 17 B, p > 0.05). However, 
when microglia became activated, cell size increased and GM1 was expressed throughout 
the entire cell body. Although the expression density of GM1 did not change, overall 
production of GM1 increased (Fig. 17 A), presumably due to the increase in cell size. 
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50 µm 
Control 
1 h 2 µM Aβ toxicity 
DIC DAPI GM1 Merged 
Figure 17.  GM1 expression measured in microglia after being activated with amyloid β 
oligomer for 1 h. (A) Microglia were activated using 2 µM of amyloid β oligomer and fixed with 4 
% PFA. Microglia were labeled with DAPI, and GM1. (B)  Average pixel intensity of GM3 
expression per microglia was measured using Image J. Intensity of GM1 in microglia after 1 h of 
exposure to 2 µM of amyloid β oligomer was compared to control. Intensity was measured for up to 
40 microglia in control and 38 microglia in 1 h of amyloid β oligomer exposure across 4 cover slips 
for each group (n=4). Results are presented as mean +/- SEM; data was analyzed by two-tailed t-
test. * indicate p ≤ 0.05. Bar indicates 50 µm for each panel 	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Section 4: DISCUSSION 
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4.1 Changes in Ganglioside Expression in Dying Neurons 	  
 Gangliosides have been associated with various roles within the CNS including 
regulation of brain development, neuroprotection and repair, and 
neurodegeneration49,58,123. Although ganglioside expression profiles in the injured brain 
have been studied through in vivo models, it has never been studied at the level of the 
neurons within the brain. Through this study, we demonstrated, for the first time, the 
temporal expression profile of simple ganglioside GM1, GM2, and GM3 and its d16:1, 
d18:1, and d20:1 sphingosine moieties in rat embryonic primary cortical neurons that are 
undergoing neurodegeneration through exposure to glutamate.  
 As expected, exposure to glutamate reduced neuronal viability in a time-
dependent manner and suggested that glutamate was an appropriate reagent to induce cell 
death to study ganglioside expression profiles in steadily dying neurons. The transient 
increase of d16:1 GM1 at 3 h and 6 h and peak of d18:1 at 6 h was an interesting finding. 
A previous study by Whitehead et al. 2011 showed through MALDI-MS that d18:1 GM1 
increased at 24 h and peaked at 7 d and decreased by 14 d of MCAO reperfusion injury in 
mice brains. Their study showed that d20:1 also increased at 24 h and peaked at 3 d.  
Furthermore, Caughlin et al. 2015 demonstrated a significant increase in GM1 
d18:1 at 3 d within brain infarct region from combined model of Aβ toxicity and 
endothlin-1 injection following treatment. These results are similar with this current 
study. The function of d16:1 relative to d18:1 and d20:1 is yet unclear but our study 
indicates that the it is being produced concomitantly with d18:1 in response to injury. 
Particularly noting the neuroprotective property of GM1 from this and previous studies, 
dying neurons may be increasing endogenous synthesis of GM1 in an attempt to self-
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protect from glutamate exposure and cell death. Furthermore, although Whitehead et al. 
2011 and Caughlin et al. 2015 showed increased expression of d20:1 in brain tissue 
following infarct injury, our study did not show significant change in dying neurons. This 
may be due to the fact that there are differences in the expression patterns of sphingosine 
moieties in embryonic brains and adult brains. Previous work showed that there are 
higher quantities of d20:1 sphingosine moieties found in adult mammal brains33. For this 
reason, we also looked at the relative abundance of d16:1, d18:1 and d20:1 ganglioside 
species in embryonic neuron culture and compared to 4-month adult rat brain. Our study 
using ESI-MS accurately showed that d18:1 was the most abundant ganglioside both in 
embryonic neurons as well as 4-month adult brains which is consistent with previous 
studies34,35. Furthermore, d20:1 GM1 was increased in adult brain in comparison to 
embryonic neuronal cultures which is also consistent with previous studies. These 
evidences suggests that there may not have been sufficient expression of d20:1 in 
embryonic cortical neurons in our study, to show a measurable response to injury. It is 
also interesting to note the immunofluorescence data that there was a significant increase 
in the GM1 expression within neurons exposed to glutamate that were not labelled with 
PI. This suggests that the increase in GM1 expression in dying neurons observed through 
ESI-MS stemmed from the few live neurons which up-regulate GM1 synthesis in order to 
counteract the damage induced by excess glutamate. 
 This study also investigated the expression profile of GM2 and GM3 in dying 
neurons as they are associated with cellular death101–105,123,125. We predicted that these 
species would not be present in uninjured control neurons. However, ESI-MS revealed 
that both GM2 and GM3 and its d16:1, d18:1, and d20:1 sphingosine moieties were 
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present in the control groups, indicating that GM2 and GM3 is not toxic at every stage of 
development. However, levels of GM2 in 4-month adult rat brains were significantly 
lower in comparison to embryonic neurons which is consistent with previous studies. 
Although in mature healthy adult mammalian brains, GM2 and GM3 were undetectable 
or were present in trace amounts27, in the developing brain of mammals, GM2 and GM3 
are prominently expressed as they are believed to play regulatory roles in 
development20,104. As many studies in the literature indicate that expression of GM2 and 
GM3 is increased in injured brains, we predicted that levels of GM2 and GM3 will 
increase in cortical neurons exposed to glutamate. Interestingly and contrary to our 
predictions, GM2 and GM3 did not show significant difference in neurons exposed to 
glutamate compared to uninjured control neurons. In order to visually confirm that there 
was a lack of change in the expression of GM3 in dying neurons, immunofluorescence 
was performed to on the GM3 gangliosides. However, the antibody was not able to detect 
any GM3 expression in the rat primary embryonic cortical neurons in culture. This 
suggests that ESI-MS is far superior in sensitivity than the antibody’s ability to bind.  
One possible explanation of the lack of significant change in the expression 
profile of GM3 and GM2 in the dying cortical neurons from this study may be that the 
variation in the ESI-MS peak intensities was too large between replicates to achieve 
statistical significance. By increasing the number of replicates, there might have been 
significant increase in the expression levels of GM2 and GM3 in injured neurons exposed 
to glutamate. Another potential explanation is that the increase in GM2 and GM3 
expression reported in previous studies using in vivo models are due to other cells within 
the brain that are responding to injury.  
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4.2 GM1 Pretreatment 	  
In this study, pretreating the rat primary embryonic cortical neurons with 
exogenous GM1 showed increase in cellular viability when exposed to glutamate. Our 
hypothetical mechanism of GM1 neuroprotection was that as the level of GM1 decreases 
in the dying neurons, exogenous addition of GM1 would replenish the depletion of the 
endogenous GM1 within the membrane. Although ESI-MS data suggests that there was 
no significant decrease in the level of GM1 in dying neurons, by 1 h of exposure to 
glutamate, there was a trend towards a decrease in GM1 ganglioside in these neurons. 
Furthermore, Caughlin et al. 2015 also showed in their study that in small brain infarcts 
of rat brains treated with endothelin-1, there was a slight decrease in GM1. This suggests 
that our hypothesis is a potential mechanism in which GM1 provides neuroprotection in 
dying neurons. Overall, our data suggests that dying neurons may increase synthesis of 
GM1 as an inherent mechanism to counteract environmental insult. By adding exogenous 
GM1, it replenishes the depleted GM1 in the membrane of dying neurons to enhance 
cellular viability in neurons exposed to glutamate. 
   
4.3 Ganglioside Expression in Activated Microglia 	  	   The lack of change in ganglioside GM3 was of particular interest considering 
Whitehead et al. 2011 showed an increase in GM3 in mice brain infarcts after 3 d and 7 d 
of MCAO reperfusion injury around the border of the infarct region. We were led to 
believe that the source of GM3 increase was from other cells in the brain. We were 
particularly interested to observe the GM3 ganglioside expression in microglia because 
the time frame of GM3 expression increase at 3d and 7d, and decrease at 28 d, in 
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Whitehead et al. 2011 study closely correlates with microglial activity as they are the first 
cells to migrate to CNS injury159 (Fawcett JW et al. 1999). The final stage of CNS injury 
is glial scarring, predominantly responsible by astrocyte activity159. If astrocytes were 
responsible for GM3 production, the increase would have persisted until 28 d of MCAO 
damage, which it did not. 
One way to activate microglia is through exposure to soluble amyloid beta 
oligomer 1-42 155–157. Significantly increased expression of GM3 in activated microglia 
compared to inactivated controls was an intriguing finding. This confirmed our 
hypothesis that GM3 detected in injured brain is attributed to microglial activity. 
Furthermore, although astrocytes showed some GM3 staining, most of the GM3 staining 
were positive in cells that were not stained with GFAP. This indicated that GM3 increase 
happens primarily in microglia and not astrocytes. In peripheral tissues, macrophages 
have synonymous function as microglia in the CNS. A study by Bobryshev et al. 1997 
showed that there was an increase of GM3 ganglioside expression within the inflamed 
regions of the atherosclerotic lesions160. It was further investigated that macrophages that 
infiltrated the atherosclerotic plaques had increased expression of GM3 and GM3 
synthase compared to those of non-diseased intima layers160,162. It is believed that the role 
of GM3 in macrophages is a modulator that assists in the differentiation of monocytes to 
macrophages162. This may also explain our observation with activated microglia in this 
study. A possible reason for the increase in the levels of GM3 in activated microglia 
compared to the inactive control might be that the synthesis of GM3 may have increased 
in order to differentiate and activate these cells as a response to inflammation. Similar to 
how active macrophages deposit GM3 in atherosclerotic lesions, active microglia may 
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also release GM3 as a product of activation into the surrounding brain tissues. This may 
explain the increase in GM3 levels observed within infarct regions of mice brains at 3 d 
and 7 d following MCAO treatment27 which was not observed in dying cortical neurons 
in our study. Toxic properties of GM3 to neurons may also exacerbate neuronal death in 
infarct regions.  
It was intriguing to note that GM1 was detectable in both inactive and activated 
microglia. Although the intensity of GM1 expression through optical densitometry 
revealed no significant difference between inactive and activated microglia, the overall 
GM1 expression was increased in activated microglia. Moreno-Altamirano et al. 2007 
showed evidence of two subtypes of monocytes in which one subtype produced low GM1 
and another subtype that expressed high levels of GM1163. GM1 expression levels also 
correlated with the macrophage endocytic capabilities in which cells that expressed more 
GM1 were more endocytic. Furthermore, the percentage of monocytes that expressed 
more GM1 increased during differentiation from monocytes to macrophages, suggesting 
that GM1 may play a role in helping monocytes transform into active macrophages. This 
evidence suggests that the activated microglia in our study might be increasing synthesis 
of GM1 as it differentiates from inactive microglia to increase its endocytic capability in 
response to injurious stimuli; in our case amyloid beta oligomer. 
 
4.4 Study Limitations 	  
	   The first limitation to this study is the availability of antibodies used to label the 
gangliosides in rat embryonic cortical neurons. Although GM1 and GM3 were 
commercially available, a GM2 antibody that was suitable for immunofluorescence was 
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not available. A previous study using antibodies against GM2 ganglioside were custom 
made from supernatants from hybridoma clones105, to which our lab did not have access. 
For this reason, we were unable to supplement the ESI-MS data with 
immunohistochemistry of GM2 expression profiles in dying neurons.  
 Another limitation to this study is that the antibodies used against gangliosides 
cannot distinguish between the d16:1, d18:1 or the d20:1 sphingosine moieties of 
gangliosides. Proteins that bind to specific gangliosides recognize the specific sugar chain 
combination27,43,44 of the molecule. Therefore distinguishing the sphingosine moieties 
based on different carbon lengths, which are embedded within the membrane by 
antibodies was not possible. Consequently, the immunofluorescence images of GM1 and 
GM3 antibody is not specific to a particular sphingosine moiety.  
 Another potential limitation of this study is the possibility of ganglioside 
antibodies cross reacting with another species of gangliosides. For example, anti-GM1 
antibody collected from serum of patients with Guillain-Barré syndrome showed some 
cross reactivity with GD1b ganglioside164. As a result, it is a possibility that the GM1 
antibody used in this study showed some reactivity to GD1b. This was resolved by ESI-
MS which is superior than immunohistochemistry as it has the ability to accurately 
distinguish the different species of gangliosides and its sphingosine moieties based on its 
mass to charge ratio.  
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4.5 Future Studies 	  
	   This is the first study to analyze how gangliosides are regulated in pure cortical 
neurons undergoing neurodegeneration.  We used glutamate to model neurodegeneration 
as it provides a basis in which how gangliosides are regulated in dying neurons. Now that 
we have a better understanding of simple ganglioside expression profile changes in dying 
neurons, we can investigate ganglioside expression profile changes in models that have 
more clinical relevance. A logical next step would be to analyze ganglioside expression 
profiles in neurons by inducing death by oxygen-glucose deprivation (OGD), exposure to 
Aβ oligomer, or MPTP, to mimic stroke, AD, and PD, respectively.  
 In this study, we have demonstrated the changes of GM1 and GM3 expression 
profiles in control and activated microglia through immunofluorescence. This data, 
combined with ganglioside expression changes in cortical neurons, suggests that the 
accumulation of GM3 in the brain of in vivo and in situ models likely stem from 
microglial activity. To avoid antibody cross reactivity and to selectively detect d16:1, 
d18:1, and d20:1 sphingosine moieties of gangliosides, ESI-MS should be performed on 
the control and activated microglia in the future. This would give us an accurate 
understanding of how gangliosides are regulated in microglia and its roles in 
inflammation and neuronal death. Once we have a full understanding of the ganglioside 
metabolism in activated microglia and its interaction with cortical neurons in 
neuroinflammation, perhaps we can manipulate certain pathways to reduce GM3 or GM2 
accumulation to prevent or attenuate neuronal death in neurological diseases.  	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Summary of Key Findings 
 
1. Glutamate induced neuronal death in time-dependent manner. 
2. Compared to uninjured control neurons, d16:1 GM1 increased in neurons exposed 
to 3 and 6 h of glutamate, d18:1 GM1 increased in neurons exposed to 6 h of 
glutamate, but there was no significant difference in the expression pattern of 
d20:1 GM1 in neurons exposed to glutamate. 
3. Compared to uninjured control neurons, GM2 expression did not show significant 
difference in neurons exposed to glutamate. 
4. Compared to uninjured control neurons, GM3 expression did not show significant 
difference in neurons exposed to glutamate. 
5. d18:1 sphingosine moieties were the most commonly found gangliosides in rat 
embryonic cortical neurons. 
6. There was a significant increase in the level of d20:1 GM1 gangliosides relative 
to d16:1 in healthy 4-month adult rat brain compared to rat cortical embryonic 
brain. 
7. Immunofluorescence indicated a significant increase in the number of GM1 
positive and PI negative neurons compared to the control group  after exposure 
to glutamate. 
8. Pretreatment of cortical embryonic neurons with exogenous GM1 24 h before 
glutamate exposure showed significant increase in cellular viability. 
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9. GM3 ganglioside was undetectable in inactive microglia. When microglia were 
activated with amyloid beta oligomer, levels of GM3 ganglioside expression 
increased. 
10. Both inactive and activated microglia show expression of GM1 but there was an 
increase in the overall production of GM1 in activated microglia. 
	  
Conclusions 
 Primary rat cortical embryonic neurons that underwent neurodegeneration 
following exposure to glutamate showed increase in GM1 d16:1 and d18:1 while GM2 
and GM3 did not show significant differences. When neurons were pretreated with GM1 
before glutamate exposure, cellular viability increased. Together, these findings suggest 
that GM1 has neuroprotective properties and that neurons may be upregulating its GM1 
synthesis to counteract the damage induced by glutamate exposure. Furthermore, when 
microglia were activated, GM3 expression was increased. These findings suggest that the 
increased levels of GM3 in injured brain models may stem from microglial activity (Fig 
18). 
 This study provides critical evidence for ganglioside metabolism in 
neurodegeneration in pure neurons and the link between microglia to provide an 
overview of ganglioside expression profiles of in vivo and in situ models. Accumulation 
of GM3 has been shown in models of neurodegeneration including stroke, AD, and 
Niemann-Pick disease27,104,124. By understanding that GM3 is primarily produced from 
activated microglia as this study suggests, we can use GM3 in the microglia as a target to 
ameliorate neurodegeneration in clinical settings. 
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Figure 18. Hypothetical schematic of ganglioside expression in the CNS during 
glutamate excitotoxicity. Once brain is exposed to glutamate, neurons become 
injured. In response, some neurons increase their synthesis of GM1 in order to 
protect themselves from further damage. In parallel, in response to neuronal injury, 
microglia are transformed into activated state and increase their synthesis and 
expression of GM3. GM3 ganglioside is released into the extracellular environment 
that acts in a paracrine manner to induce further damage to neurons. 
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MS/MS Spectra of Ganglioside GM1, GM2 and GM3 
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  d18:0	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2014  NSERC Canada Graduate Scholarship.   
Awarded for strong academic and research experience. Competition: 238 NSERC 
applicants university-wide, 25 awarded across all faculties. Value: $17,500 
 
2013 & 2014  Western Graduate Research Scholarship, Western University 
Awarded for strong academic performance. Value: $1,500 
 
2010-2013  Dean’s Honor List, Western University 
  Named for academic excellence in university 
 
2012  NSERC Undergraduate Student Research Award, Western University. 
Awarded for academic achievement. Competition: 54 applications to Schulich 
School of Medicine and Dentistry – Western University, 17 awarded. Value: 
$6,000 
 
2009-2013  Continuing Admissions Scholarship, Western University 
  Awarded for academic average of 95%+ in high school 
  Value: $10,000 ($2,500 per year – renewable) 
   
 
 
Research Experience  
 
2013  Summer Research Student, Western University 
Optimizing the sublimation of 1, 5-diaminonaphthalene matrix onto rat brain tissue 
for image processing through matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI-MS) technique 
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Supervisor: Dr. Shawn Whitehead 
 
2010  Summer Clinical Research Student, Baycrest Hospital, Toronto, ON 
  INCAS - Integrated Neurocognitive Assessment System 
  Supervisor: Dr. Jon Ween 
 
 
Publications, Presentations and Abstracts 
 
2015  Caughlin S, Hepburn S, Park DH, Jurcic K, Yeung K, Cechetto DF, Whitehead 
SN. Increased expression of simple ganglioside species GM2 and GM3 detected by 
MALDI Mass Spectrometry Imaging in a combined rat model of Abeta toxicity and 
stroke. PLoS One. 2015 June 18; 10(6):e0130364. doi: 
10.1371/journal.pone.0130364. eCollection 2015 
 
2015  Caughlin S, Park DH, Hepburn J, Jurcic K, Yeung KKC, Cechetto DF, Whitehead 
SN. Poster (May 1): Increases in simple gangliosides GM2 and GM3 detected 
using MALDI IMS in a rat model of AD and stroke. Conference: Southern Ontario 
Neuroscience Association (SONA), Hamilton, ON, Canada 
 
2015  Park DH, Lajoie GA, Whitehead SN. Poster Presentation (April 1): Electrospray  
ionization mass spectrometry detects changes in expression profile of gangliosides 
neurodegenerating rat primary cortical neurons. Conference: London Health 
Research Day, London, ON, Canada 
 
2015  Caughlin S, Hepburn S, Park DH, Jurcic K, Yeung K, Cechetto DF, Whitehead 
SN. Increased expression of simple ganglioside species GM2 and GM3 detected by 
MALDI Mass Spectrometry Imaging in a combined rat model of Abeta toxicity and 
stroke.  
 
 
2014  Park DH, Lajoie GA, Whitehead SN. Poster Presentation (November 16): 
Electrospray ionization mass spectrometry reveals changes in expression profile of 
gangliosides in neurodegenerating rat primary cortical neurons. Conference: 
Society for Neuroscience (SFN), Washington DC, USA 
 
2014  Caughlin S, Hepburn J, Park DH, Jurcic K, Yeung KKC, Cechetto DF, Whitehead 
SN. Poster (Nov 14): Changes in gangliosides expression detected by MALDI IMS 
in a combined rat model of Alzheimer’s disease and stroke. Conference: Society 
for Neuroscience (SFN), Washington DC, USA 
 
2014  Park DH, Lajoie GA, Whitehead SN. Poster Presentation (October 23): 
Glutamate toxicity changes expression profile of gangliosides in neurodegenerating 
rat primary cortical neurons. Conference: Anatomy and Cell Biology Research 
Day, London, ON, Canada  
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2014  Park DH, Lajoie GA, Whitehead SN. Poster Presentation (May 5): Glutamate 
toxicity changes expression profile of gangliosides in neurodegenerating rat 
primary cortical neurons. Conference: Southern Ontario Neuroscience Association 
(SONA), London, ON, Canada 
 
2014  Caughlin S, Hepburn J, Park DH, Jurcic K, Yeung KKC, Cechetto DF, Whitehead 
SN. Poster (May 5). Increased expression of simple ganglioside species GM2 and 
GM3 detected by Matrix-Assisted Laser Desorption Ionization Imaging Mass 
Spectrometry in a combined rat model of Abeta toxicity and stroke. Conference: 
Southern Ontario Neuroscience Association (SONA), London, ON, Canada 
 
 
2014  Caughlin S, Park DH, Jurcic K, Yeung KKC, Cechetto DF, Whitehead SN. Poster 
(Mar 18): Examining ganglioside expression using MALDI Imaging Mass 
Spectrometry in a rat model of Aβ toxicity and stroke. Conference: London Health 
Research Day, London, ON, Canada 
 
 
2013  Caughlin S, Hepburn J, Park DH, Cechetto DF, Whitehead SN. Poster (Nov 19): 
Studying ganglioside expression using MALDI Imaging Mass Spectrometry in a rat 
model of Aβ toxicity and stroke. Conference: Society for Neuroscience (SFN), San 
Diego, California, USA 
 
 
 
Teaching Experience  
 
 
2013-2015  Teaching Assistant, MEDSCIEN 4900G: Medical Sciences Laboratory, Western  
University 
 
2013  Teaching Assistant, ANATCELL 4451F: Integrative Neuroscience, Western 
University 
 
Extra Curricular Activities 
 
2014  Volunteer in the dialysis Unit at Victoria Hospital 
I helped patients on dialysis machine perform simple physical exercises. I was able  
to build rapport and provide emotional support. 
 
 
 
 
2012-2013  VP Volunteer of Meal Exchange 
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I lead out and organized trips to various soup kitchens and food shelters across 
local London community. I also coordinated the leaders for the trips and recruited 
volunteers to help at the food shelters and soup kitchens 
 
2010-2011  Delaware Residence Soph                       
I guided first year students during orientation week and I lived in residence along 
side first year students student as their mentor. I provided first year students with 
sense of comfort and emotional support when they were in need. I also organized 
floor dinners, lead floor meetings, etc.  
 
2011   Volunteer in Leprosy Colony in Guanzhou China 
I provided basic services to leprosy patients including but not limited to: feeding, 
washing, cleaning homes, taking vitals, basic medical treatments (such as cleaning 
wounds). 
 
2010  Medical Missionary to Zambia                  
I assisted a medical doctor in providing various treatments to patients of Chilubi 
Island in Zambia. I also assisted an eye surgeon during cataract surgeries. 
 
2010   Hospital Volunteer in the ICU at Mount Sinai Hospital 
I was in charge of administrative duties including taking phone calls, refilling 
medical supplies, delivering equipment to its designated locations. I also 
interacted/comforted visitors of patients and offered Korean translation services to 
patients and families. 
 
 
 
 
